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Abstract: 
 
Glycosaminoglycans (GAGs), such as Heparan Sulfate (HS), are vital components, 
of all multicellular organisms, with confirmed roles in development, cell-cell 
communication and diseases such as dementia and cancer. As such, the interaction of 
this important group of molecules with proteins is an important process to 
comprehend and improvements to current techniques are sought. To achieve this HS 
and its structural analogue heparin, were investigated in various biological systems to 
simultaneously improve our collective knowledge of the biological systems 
employed and to improve techniques available to study them. Hen Egg White 
Lysozyme (HEWL), a model amyloid forming protein, is found to be destabilised 
with a complex of HS in the zinc (HS(Zn)) from 67.7 °C to 57.6 °C compared to 
65.3 °C in the presence of HS in the Na form (as measured by differential scanning 
fluorimetry).  These complexes were studied structurally using synchrotron radiation 
circular dichroism (SRCD) and found to contain extremely similar secondary 
structure. To differentiate these similar structures principal component analysis 
(PCA) of thermal and UV degradations of the complexes using CD were analysed. 
The HS and HS(Zn) ligands were hypothesised to interact with the two tryptophan 
residues (Trp) in the active site of HEWL. To confirm this, magnetic circular 
dichroism (MCD) was also developed as a technique to observe direct Trp:ligand 
interactions. MCD demonstrated an interaction between HS/HS(Zn) and Trp in 
HEWL using a signal at the novel position of 286 nm. Antithrombin (AT) was 
studied in relation to the active pentasaccharide drug and inactive shrimp heparinoids 
(SH) that contain the important 3-O-sulfate, thought to be key for AT activity against 
factor Xa. These active and inactive complexes were found to be structurally similar 
  
again when studied with SRCD so were subjected to UV degradation. The active and 
non-active compounds were finally differentiated via their induced stability in AT to 
thermal degradation. This important correlation challenges the current dogma, which 
relates activity with a particular pentasaccharide sequence. 2D generalised 
correlation techniques were applied to the data obtained in this thesis increasing the 
resolution of the data significantly, allowing for <1nm resolution in some examples. 
A separate method utilizing the same analysis techniques reveals subtle features 
within a spectrum, thereby increasing the information available and will be useful for 
future developments of algorithms assuring improved reliability. A new method of 
data handling is also proposed for Raman optical activity data, which allows for the 
correction of baseline drifts, enabling a series of data to be directly compared. 
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Chapter 1: General Introduction. 
 
1.1. Protein structure. 
 
Proteins are versatile macromolecules that serve crucial functions in all biological 
systems. They are made up of amino acids and are encoded for by genes contained 
within the DNA sequence of an organism.  
 
DNA is the basic code for proteins consisting of the bases adenine (A), thymine (T), 
guanine (G), cytosine (C) where A hydrogen bonds to T and G to C. The bases 
themselves are sequentially arranged along a sugar phosphate backbone, and 
sequences of 3 bases are used to encode for individual amino acids. These genetic 
codes, the order in which bases appear along the DNA strand, are translated via the 
evolutionary older mRNA, and tRNAs, into a linear sequence of amino acids. These 
then fold into unique conformations in order to perform their biological functions 
within the organism. 
 
There are 20 amino acids that make up the proteins for all organisms, and each 
amino acid has a unique side chain with its own properties and functions. The 
majority of amino acids are found in the L isomer, and at physiological pHs exist as 
zwitterions of free amino acids. The basic structure of an amino acid is shown in 
Figure 1-1. 
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Figure 1- 1: The basic structure of an L-amino acid, the R1 group is the 
location of the side chain that makes each of the 20 amino acids unique. In 
this representation, the C-H bond is facing away from the observer into the 
page. 
 
The pKa values of the amino group and carboxylic acid result in a dipolar molecule 
with a positive charge on the nitrogen and a negative charge on the carboxylic groups 
[1]. These monomers are bonded together via the loss of water to form polypeptides 
(below ~50 amino acids, and referred to as proteins above that). The bond is created 
through linking the carboxyl group to the amino group to form a peptide bond (see 
Figure 1-2).  
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Figure 1- 2: Two amino acids are covalently bonded together through the 
loss of water and the creation of the peptide bond (Red bond). 
 
There are several structurally important aspects of the peptide bond that ultimately 
influence protein structure.  It is an essentially planar bond, resulting in a flat 
uniform backbone from which the amino acid side chains protrude. Another key 
feature is the partial double bond nature of the C-N within the peptide bond. This 
bond resides somewhere between a single bond and a double bond (Figure 1-3A) as 
demonstrated by the bond lengths. A C-N single bond would have a length of 1.49 Å 
while a double bond would be shorter at 1.27 Å, the peptide bond meanwhile 
resonates at 1.32 Å, demonstrating double bond features and therefore restricts the 
rotation around this bond.  
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Figure 1- 3: A: The resonant nature of the double bond in equilibrium leading 
to the planar peptide bond. B: Shows the six atoms that are in the same 
plane with one another over a peptide bond between two amino acids. The 
peptide bond has a partial double bond demonstrated by its short C-N bond 
length. Rotation is allowed around the N-C and the C – C bonds.  
 
The peptide bonds do have some rotational flexibility around the N  C (Phi) and 
C C1 (Psi) bonds. This rotational flexibility is what gives proteins the ability to 
fold to form the common secondary structures. The folding is dictated by the 
properties of the amino acid side chains and, the order in which they are added to the 
General Introduction 
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polypeptide chain. These are then stabilised by many interchain and chain-solvent 
interactions. 
 
The side chains of amino acids are summarised in Table 1-1. They fall into several 
categories that are broadly, hydrophobic, charged and uncharged, some however, 
have specialised functions within proteins.  
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Table 1- 1: A list of the 20 amino acid properties. 
Group Name Functional 
Group 
Notes 
Special case Glycine - Unique as Achiral 
Hydrophobic Alanine - - 
Hydrophobic Valine - Non-polar, Hydrophobic 
Hydrophobic Leucine - Non-polar, Hydrophobic 
Hydrophobic Isoleucine - Non-polar, Hydrophobic, 
Additional chiral center 
Hydrophobic Methionine - Non-polar, Hydrophobic 
Special Case Proline - Side chain linked to C 
and N 
Hydrophobic Phenylalanine - Hydrophobic 
Hydrophobic Tyrosine O-H Hydrophobic 
Hydrophobic Tryptophan N-H Hydrophobic 
Uncharged Serine O-H Hydrophilic, Site of 
glycosylation 
Uncharged Threonine O-H Hydrophilic, Additional 
chiral center 
Uncharged Glutamine NH2 Hydrophilic 
Uncharged Asparagine NH2 Hydrophilic 
Special case Cysteine S-H Two can Oxidise to form 
disulfide bond 
Charged Lysine NH3
+
 Full positive charge 
Charged Arginine NH2/NH3
+
 Full positive charge 
Charged Histidine - Full positive charge/No 
charge at pH 7, pKa 6.0 
Charged Glutamic Acid COO
-
 Negative charge 
Charged Aspartic Acid COO
-
 Negative charge 
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The amino acids encoded for by the genetic code are joined together with peptide 
bonds to form the primary sequence of proteins. These amino acids must then fold 
together into local secondary structures to ultimately form the overall tertiary 
structure of the folded protein. This is achieved through various interchain and 
solvent-based interactions, predominantly through non-covalent bonding. Many of 
these interactions are heavily dependant on charges carried by the amino acid groups, 
and these are summerised in Table 1-2. 
 
Table 1- 2: A list of (protein side chain) pKa values, and their charge 
transitions at this value. 
Group pKa Charge 
Aspartic Acid 4.1 0  - 
Glutamic Acid 4.1 0  - 
Histidine 6.0  +  0 
Amino Group 8.0  +  0 
Cysteine  8.3 0  - 
Lysine 10.8 +  0 
Tyrosine 10.9 0  - 
Arginine 12.5 +  0 
 
The charges on the chemical groups listed in Table 1-2 contribute to the folding of a 
protein through non-covalent forces. The non-covalent forces are relatively small, 
but numerous so collectively are essential for correct folding of proteins. Forces 
affecting the correct folding are Van der Waals forces, hydrogen bonding and 
dispersion forces. Dispersion forces are the electrostatic attraction of molecules that 
are given small dipole moments by the oscillation of the electrons, these are 
General Introduction 
 8 
countered by the repulsion of electron shells from one another, although the overall 
effect is a net attraction. One of the most important forces in protein secondary 
structures are hydrogen bonds, and a vital acceptor/donator pair for this is the protein 
backbone which has a small negative charge on the C=O and a small positive charge 
on the amino group allowing a hydrogen bond to form within the backbone and 
stabilizing the secondary structures formed. The major hydrogen bond forming 
groups are described in Table 1-3, along with the bond distances (between donor and 
acceptor atoms) as a direct measure of bond strength. 
 
Table 1- 3 A list of important groups involved in inter-chain hydrogen bonding 
in protein structure and their relative bond lengths (Å), representing the bond 
strengths. The amide carbonyl hydrogen bond is essential in protein 
secondary structure. 
Name of hydrogen bond Groups Distance between atoms (Å) 
Hydroxyl-hydroxyl O-H…….O-H 2.8 ±0.1 
Hydroxyl – carbonyl O-H…………C=O 2.8 ±0.1 
Amide – carbonyl N-H………….C=O 2.9 ±0.1 
Amide – hydroxyl N-H……….O-H 2.9 ± 0.1 
Amide – imidazole nitrogen N-H……….N= 3.1 ± 0.2 
Amide - sulfur N-H……….S- 3.7  
 
These hydrogen bonds serve to stabilise interactions within the protein chain to form 
the essential secondary structures in proteins. These can broadly be summarised as 
-helix, -sheet, -turns and random coils. Alpha helical structures are tight coils of 
the protein backbone with the amino acid side chains sticking outwards at regular 
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intervals. Although left-handed helicies are possible, they exist predominantly in a 
right-handed form, as this is more energetically favourable. In this arrangement the 
amino acids are tightly packed, with one amino acid being 1.5 Å higher up the helix 
than the previous at a 100° angle. This twist in the amino acid at each residue results 
in one full turn of the helix taking on average 3.6 amino acids and enables the CO 
and NH groups to line up, allowing extensive hydrogen bonding. The CO group in 
the backbone hydrogen bonds to the NH group of the amino acid 4 places further 
down the sequence and the alignment of all the amino acids enables every amino 
acid to be hydrogen bonded to another, excepting the extremities of a helix. This 
results in a stable structure and can be seen in Figure 1-4. 
 
 
Figure 1- 4: A representation of a right-handed -helix and the hydrogen 
bonding that stabilises the structure.  
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-sheets are strands of a protein that are in a flat extended form and have hydrogen 
bonding stabilizing them. These structures have the amino acids in a much more 
elongated form compared to -helix structures with an average of ~3.5 Å between 
each residue. The amino acids side chains in -sheets alternate and protrude from 
opposing sides of the plane of the backbone of the strand. There are two forms of -
sheet; parallel where the two strands both run in the same direction, and antiparallel 
where the direction of the protein backbone is in opposite directions. -sheets in 
proteins  can exist in one, the other, or both forms within the same larger structure 
within a protein and are commonly found with 4 or more strands stacked upon one 
another.  The hydrogen bonding is different for each example with the antiparallel 
sheet being a simple example of each CO group lining up and bonding with its 
opposite NH group. However, the parallel -sheet each amino acid bonded to two 
other amino acids, the NH group bonds with the CO of an amino acid opposite and 
the CO group of the same residue is then bonded to the NH group of an amino acid 
two residues further down the chain. This can be seen in Figure 1-5. 
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Figure 1- 5: A representation of the hydrogen bonding present in anti-parallel 
(A) and parallel (B) -sheet secondary structures. 
Another common structure is the -turn in which the direction of a protein backbone 
can be reversed, essential in forming globular proteins. These are stabilised by the 
use of a hydrogen bond between the CO group of amino acid i and amino acid i+3 
shown in Figure 1-6.  
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Figure 1- 6: A representation of a -turn in which the carboxyl group of the 
amino acid i is hydrogen bonded to the amino group of i+3. 
 
There are also more loosely defined structures referred to collectively as random 
coil, or loops. There are no regular or periodic structures within these loops, 
however, they are often rigid and defined. They are found at the surfaces of proteins 
and can be important in protein:protein and protein:ligand interactions.  
 
Tertiary structure allows pairs of cysteine amino acids to come into contact with one 
another and form disulfide bonds through an oxidation reaction. These are used to 
stabilise structures within the protein, and are especially prevalent in extra-cellular 
proteins. Once the production of a protein is completed, and as it folds into its native 
state, the proteins can then be modified in various ways, for example glycosylation 
and phosphorylation. These modifications can further modify the structure, function 
and stability of the protein. 
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Hydrophobic forces also play a significant role in correct protein folding in addition 
to the binding energies discussed. Three forces also have a large impact on the 
overall stability of the protein as the hydrophobic amino acids are preferentially 
buried in the center of proteins to avoid contact with polar solvents, such as in 
aqueous environments.  An overview of the non-covalent forces acting upon a 
protein are presented in Table 1-4. 
 
Table 1- 4:  An overview of the energies of non-covalent interactions that act 
upon a protein to create the native conformation in an aqueous solution. The 
hydrophobic effect value given is for a single CH2  bond [2]. 
Type Example Binding Energy 
(Kcal/mol) 
Dispersion forces Aliphatic 
hydrogen 
-0.03 
Electrostatic 
interaction 
Salt bridge -5 
Hydrogen bond Protein 
backbone 
-3 
Hydrophobic 
forces 
Phenylalanine 
side chain 
1 
 
This thesis will describe studies of the average secondary structures of proteins, and 
how they change upon an interaction with a GAGs in solution for which there is a 
dearth of available techniques. The main technique used for this purpose is circular 
dichroism (CD) and is described in section 1.4 of this general introduction. 
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1.2. Glycosaminoglycans. 
 
Glycosaminoglycans (GAGs) are long linear negatively charged polysaccharides. 
GAGs are thought to have evolved by the evolutionary clade, Eumetazoa [3]. They 
have become an essential component of the extra cellular matrix (ECM), present on 
practically all mammalian cells [4]. There are several polysaccharides within the 
GAG family classification; hyaluronic acid (HY), the two main chondroitin sulfates 
A and C (CS-A and CS – C), dermatan sulfate (DS), keratan sulfate (KS), heparan 
sulfate (HS) and heparin. With the exception of HY, the only unsulfated GAG in the 
family all other members of the GAG family contain some level of O-sulphation. 
The development of HS regulatory proteins has been associated with the onset of 
multi-cellular life. Some simple multi-cellular organisms have been shown to possess 
components of the HS biosynthetic equipment, and they have even been found in 
some unicellular organisms [5]. They are naturally found attached to proteins 
forming proteoglycans (PG), and each PG can have up to as many as 100 GAG 
chains attached [4]. HS and heparin are unique in that they also poses varying 
degrees of N-sulfation through their chains [6].   
 
This work focuses on the GAG HS, and the closely related heparin. They share the 
same backbone disaccharide repeating units of -D-glucuronic acid-(14)--D-
glucosamine or -L-iduronic acid-(14)--D-glucosamine (Fig 1-7). These 
disaccharides can be modified through the additions of sulfate groups at specific 
positions. For HS and heparin these are on the oxygen on the C-2 carbon of 
glucuronic acid and iduronic acid and the glucosamine can commonly be O-sulfated 
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at the C-2 carbon position on the amine group, as well as at the C-6 carbon position. 
In rarer circumstances the glucosamine can also gain an extra sulfation modification 
at the C-3 carbon oxygen position [6].  Since it shares a common underlying 
structure, shares similar activates and is relatively abundant, heparin, the 
pharmaceutical, is used as a proxy for HS in many biochemical investigations [7,8]. 
HS is found attached to a protein component, an example of this is the protein family 
of syndicans. These are a family of PGs that have been linked with cell proliferation, 
cell-cell adhesion and ligand binding through their HS components [9].  
 
 
Figure 1- 7: A representation of the major repeating unit within heparin and 
Heparan sulfate, in its tri-sulfated form. Image is reproduced from reference 
[10] 
 
Heparin and HS biosynthesis takes place within the lumen of the endoplasmic 
reticulum-trans Gogi network inside cells. Heparin is found in mast cells of 
connective tissue, and HS and heparin are differentiated in various ways, one of 
which is the N-sulfation (NS) – N-acetylation (NA) ratios, with heparin having a 
<2:1 ratio of NS to NA [11]. Heparin is also cleaved from its PG by a specific endo-
-D-glucuronidase [12] to produce heparin fragments of 3 – 30 kDa. HS 
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polysacchairde chains are longer than heparin with an average of ~30 kDa, as 
opposed to the ~15 kDa of heparin chains [13] and, unlike their heparin counterparts, 
HS chains have some organisation present, with NA and NS domains being apparent 
[14]. Heparin and HS are made up of combinations of 4 hexuronic acids and 6 
different glucosamines in disaccharide units and share the same biosynthetic pathway 
[15].  
 
The initiation of the heparin and HS biosynthetic pathway is the xylosylation of a 
serine residue, followed by addition of a (14) Gal, a (13) Gal, (13) GlcA 
and finally an (14) linked GlcNAc residue [16]. This final GlcNAc 
monosaccharide is what determines that this will ultimately become a HS/heparin 
chain, while the addition of a GalNAc instead would result in a CS or DS chain 
being polymerised. Following the GlcNAc addition, there is a stepwise addition of 
the unmodified backbone units of GlcA and GlcNAc to the non-reducing end of the 
polysaccharide chain. The alteration of monosaccharides is achieved through 
apparent substrate specificity of the enzymes [17,18,19]. This polysaccharide chain 
is then modified sequentially by a number of enzymes, the whole process taking <1 
minute from start to finish [20]. The first modification step, and a key regulatory step 
in the overall modification of the chain, is the deacetylation of the N-
actylyglucosamine residues. This step is a key regulatory step as it is a prerequisite 
of N-sulfation, which is the next step performed on the now free amino groups. 
These two reactions are thought to be coupled in vivo [21] and are catalysed by the 
same protein [22]. Once the N-sulfation of the glucosamine is completed, another 
key regulatory step that, if not performed, prevents the subsequent modification of 
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the D-glucuronic acid [23] is epimerisation at the C-5 position to form L-iduronic 
acid (IdoA). The IdoA can then be modified at the C-2 position with O-sulfation, and 
also the GlcNS can be O-sulfated at the C-6 position [15,20,23,24,25]. The transfer 
of sulfates onto their respective groups requires a 3′-phosphoadenosine 5′-
phosphosulfate (PAPs) as a sulfate donor. This is known to influence the properties 
of the degree of N-sulphation within a HS chain [26].  In addition to these 
modifications, there are two rarer modifications that can occur, the glucuronic acid 
can be O-sulfated at the C-2 position and the C-3 of GlcN.  The biosynthesis of HS 
and heparin are likely to entail some distinct features, not accounted for here, 
because heparin lacks the domain structure of HS. The domains of HS allow for 
active NS regions of highly modified sugars, hypothesized to be the regions of most 
biological activity [27] to be separated by the more flexible, but much less modified, 
NA domains. The ratio in HS for NS and NA units is reported to be around 50:50, 
but this can change depending on the tissue type, and this ratio is observed in tissues. 
However, when the required components are added together in vitro, a ratio 
approaching 75:25 (NS:NA) appears implying some external regulation mechanism 
[28].  
 
The above mechanism is the conventional view of HS and heparin biosynthesis, it is 
however not the only proposed route for creating the required products. A new 
mechanism has been proposed following an overview of the available data in which 
the large redundancy in the structural geometries was noted for different sulfation 
patterns [29,30]. The analysis conducted was based upon the known substrate 
specificity for the enzymes and employing an approach based on graph theory to 
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reveal an efficient tree structure for the biosynthetic pathway. This tree structure has 
two main branches based around the initial N-sulfation event. The division of the 
biosynthetic pathway in this manner, coupled with the restrictions on substrate 
specificities leads to the abundant structures all being on a single branch, whilst rarer 
structures lie on the minor branch [5]. This branching of the biosynthetic pathways 
requires that the C-5 epimerase have dual substrate specificity and is able to convert 
both the GlcA-GlcNA and GlcA-GlcNS into their respective IdoA forms, or the 
existence of a separate epimerase for this particular substrate. The product of this 
hypothesized epimerase has been observed however [31]. There is evidence to 
support the hypothesis that the same epimerase acts on both substrates as a knockout 
of this enzyme results in no IdoA being detected at all, and an increase in GlcA-2S 
products [32]. The synthetic route is also supported by analysis of the HS present in 
the lethal knockout of the C-5 epimerase [33]. This proposed route of biosynthesis 
has two major benefits for the biological system, firstly it is very efficient in that all 
6 common structures are attainable through just five enzymes and 4 steps. This 
system also provides a mechanism which creates a large variety of possible 
structures through alterations in glycosidic linkage positions or ring conformations at 
each step, so again very efficient if the overall aim of the process is to create a 
particular conformation and charge density combination [5].  The idea is then carried 
on to a hypothetical situation where single position frame shifting is able to take 
place, providing a hypothetical mechanism whereby the blocking or modifications on 
chains can be attained and therefore a possible mechanism by which the domain 
structure of HS could be attained.  
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The synthesis of heparin and HS is by no means a simple process, and there are 
many things yet to be understood about the process, which has no apparent template 
or known means of regulation.  It has been suggested, however, that there exists 
some form of feedback mechanism whereby changes to the sulf enzymes (that can 
remove sulfates from HS chains after they have been released from the Golgi) can 
influence the biosynthesis of subsequent HS chains [34]. 
 
The biosynthetic pathway and its regulation lead ultimately to the sulfation sequence 
of heparin and HS molecules. There has been much work in studying this sulfation 
sequence in an attempt to link this aspect to biological activity in a sequence 
specificity manner [35,36,37]. This cumulated in the now widely used 
pharmaceutical based on an antithrombin (AT) binding pentasaccharide sequence, 
based around the rare 3-O-sulfate upon the GlcNS saccharide, that is known to 
increase the activity of this important blood anti-coagulant enzyme [38]. The details 
of this discovery are discussed within the introduction to Chapter 5. There has, in 
subsequent studies, been evidence of a correlation not only of the sulfation pattern, 
but also charge density and binding [39], although this correlation could be attributed 
to binding experiments that contain an inherent bias towards more charged molecules 
[36]. The most likely requirement for biological activity appears to be a combination 
of several factors; appropriate conformation, charge density and molecular flexibility 
to allow binding to the complementary protein surface via interactions, 
predominantly, with lysine and arginine side chains [6].  This idea is supported by 
the observation that non-GAG plant polysaccharides that have similar charge density 
and conformation to active GAGs are capable of inducing activity in Fibroblast 
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Growth Factor 2 (FGF2) cell signalling and also in vascular endothelial growth 
factor [40,41,42]. The pentasaccharide sequence, the sugar that has a reported 
specific sequence – activity relationship for to AT changes its binding properties 
when it is extended, and is able to have some leeway regarding sulfation positions, 
again lending support to the importance of the overall conformation, and charge 
distribution [43,44]. The issue is further confounded by the additional knowledge 
that not only will the overall charge density and sulfate sequence of a HS molecule 
alter its biological activity, but so will a change in its cation state [45,46]. 
 
 A difficulty faced when attempting to address the question of sequence-activity 
relationship is the use of heparin libraries of limited structural diversity [47]. Another 
is the difficulty of obtaining pure oligosaccharides from an initially mixed pool. 
There are currently few examples beyond the AT example that demonstrate a 
sequence specificity for protein binding and activity [48] and this is further addressed 
in Chapter 4. HS and heparin protein binding is also complicated by overlapping 
protein binding sites [49], as well as a degree of redundancy [50], for example in the 
case with the hepatocyte growth factor requiring any two sulfates in the disaccharide 
to bind, regardless of position [43].  
 
1.3. The heparan sulfate interactome. 
 
HS interactions with their various protein ligands are enabled through location of 
their core proteins, of which there are two main families; the syndican family of 
which there are four, and the glipican family there are six. The syndicans are a 
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family of proteins that contain a transmembrane core protein to which either HS or 
CS chins are attached. These polysaccharide chains then extend out into the 
pericellular matrix [51].  The other major family of proteins that HS is associated 
with is the glypicans. These are a group of proteins that are anchored to the plasma 
membrane via a hydrophobic region at the C-terminal. HS attachment is restricted to 
only the last 50 amino acids, keeping the chains relatively close to the membrane 
[52]. HS chains are also known to be present on a range of proteins present in the 
ECM such as perlecan, agrin, and collagen XVIII [53]. 
 
Heparin and HS bind to, and affect the biological activities of, a wide range of 
proteins primarily in the ECM. In an extensive systems biology investigation into the 
proteins that interact with heparin and HS, 435 proteins were found [54], covering a 
wide range of biological activities. This expands on the 216 proteins found to bind 
HS just 3 years previously [55].  The group of proteins that interact with HS and 
heparin, termed the ‘HS interactome’, includes many important classes of biological 
activity. HS has been shown to have a role in the infection of mammals [56], and 
plays a key role in embryonic development [57]. In addition, HS has been shown to 
have biological activity in the inflammation and immune response [58,59], 
angiogenesis [60], morphogenesis [61], ECM assembly [62] and the coagulation 
cascade [63]. 
 
The bioinformatic approach used in the study of heparin/HS interaction networks has 
revealed several key pieces of information; First it is noted that the interactions 
formed by HS and heparin with ECM proteins are very highly clustered in 
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comparison to the interaction networks of non-heparin binding proteins. This places 
HS at the centre of many interaction nodes between signaling cascades, potentially 
playing an important role in the mediation of information between the extra and 
intracellular signaling pathways [54]. 
 
Further analysis of the heparin binding proteins (HBP) shows a structurally very 
diverse group of proteins. This could be a result of the many modes of binding 
thought to be available through the structural diversity available in GAGs. Analysis 
of the evolution of these HBPs shows a strong Pearson’s correlation coefficient 
between their evolution and the complexity of the organism, suggesting a need for 
HS interactions in higher animals. This suggestion is reinforced when studying the 
presence of HS biosynthetic enzymes, again their presence correlating with higher 
organisms [54]. 
 
1.4. Methods overview. 
 
There are many methods for studying protein structure and these can come in various 
degrees of resolution, precision, and accuracy. Often seen as a gold standard in 
protein structural analysis is X-ray crystallography. This technique relies on the 
creation of crystals which are then subjected to high intensity X-rays which interact 
with the atoms of the protein and diffract to give a specific pattern that is directly 
linked to the organisation of the atoms within the crystal, and therefore the structure 
of the protein. While this technique provides extremely good resolution, in the best 
case resolving every atom individually, it suffers from several issues. Firstly, in 
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relation to the work to be undertaken herein, cystallisation cannot be achieved when 
working with highly flexible and heterogeneous GAG polysaccharides. It also suffers 
in that proteins are studied in non-native conditions that lack buffer, salt, and 
physiological pH conditions.  
 
Nuclear Magnetic Resonance (NMR) is another high-resolution technique that is 
suited to studying protein structure. This technique, unlike x-ray crystallography, is a 
solution-based method, enabling physiological conditions to be mimicked during 
experiments. This method, in simple terms, probes the local environment of NMR 
active nuclei (eg 
1
H, 
13
C, 
15
N), which is altered depending on how they are 
interacting with the rest of the protein or solvent and thereby provides information on 
protein conformation. This technique can be used to observe interactions in solution, 
however, a major drawback is the broad signals for large and immobile proteins and 
polysaccharides. It is difficult to study protein:GAG interactions using this technique 
for several reasons such as the size limit (30 kDa) and fast relaxation times of 
proteins, the multiple binding sites on GAG polymers combined with sample 
precipitation and the need for isotropically labeled protein make it a challenging 
technique. The signals from both components overlap, the size and heterogeneity of 
HS samples with multiple binding modes and line broadening. It has been possible to 
study some protein:GAG oligosaccharide interactions via NMR for heparin/HS 
interactions with FGF 1 and 2 [64,65] and has also been achieved with a 
tetrasaccharide – protein interaction following cross-linked basic side chains [66]. 
NMR is also one of the key techniques for studying the conformation of GAGs in 
solution. It is able to provide information on ring puckering, glycosidic linkage 
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conformation and average sulfation positions with a sample [29,30,67,68,69,70]. 
NMR is also capable of investigating the overall flexibility of GAGs, as shown in a 
study on the flexability of the NA domain in HS with the use of 
15
N labeled HS [43].  
There are efforts to advance the structural information available through NMR via 
chemical and enzymatic methods to synthesise heparin oligosaccharides that are 
13
C 
and 
15
N labeled [71,72]. NMR requires relatively high concentrations of sample (0.2 
– 2 mM [73]), which can lead to aggregation in some proteins. For structural work to 
take place, NMR stable isotopes (
13
C and 
15
N) are required, combined with 
multidimensional NMR experiments [73].  
 
Small angle x-ray scattering (SAX) is another option to look at protein conformation 
in solution through its overall shape in solution and is very low resolution. It is 
however very useful for studying aggregation. This technique can provide 
information regarding the overall shape of a molecule in solution. SAX is currently 
limited to this type of analysis as the molecule is free to rotate in solution resulting in 
the gathering of the average scattering across all possible orientations and is thus a 
low-resolution technique.  
 
X-ray scattering is a technique that has been used to study the properties of some 
heparin oligosaccharides, finding the heparin to be semi-rigid, extended molecules in 
solution [74]. Another little used technique being developed to study GAGs in 
solution is Terahertz (10-12 Hz) spectroscopy which can observe the fundamental 
vibrational modes of heparin present at physiological temperatures [75].  The basis 
of this technique is that electromagnetic radiation in the THz frequency range 
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corresponds to energies of large scale molecular movements of macromolecules (or 
other materials) such as flexing of protein domains, or bending of linear 
polysaccharides, which are sometimes termed phonon modes. A frequency of about 
6 THz corresponds to energies (related by kT) that can be provided by ambient (i.e. 
biologically relevant) temperatures hence, absorbance in this range relates to the 
large scale flexing motions that occur in these molecules under natural 
circumstances. These molecular motions, of relevance to biological activities through 
such properties as enzyme activities, protein and polysaccharide dynamics and 
binding properties, cannot be observed by other spectroscopic methods, which all 
operate at higher energy levels. 
 
Another technique which has been developed in the structural biology field is cryo-
electron microscopy (cryo-EM), and recently it has been used to identify and 
characterise protein:GAG interactions [76,77]. This technique enables atomic or 
near-atomic resolution of GAG interactions at liquid nitrogen temperatures. It has 
also been used to study disordered protein and the variability found in amyloid fibrils 
[78]. Whilst cryo-EM can offer increased resolution of protein-GAG interactions, it 
lacks the ability of solution state techniques to dynamically investigate the stability 
of complexes or the binding kinetics of protein-ligand interactions. 
 
Infrared spectroscopy (IR) has previously been used in the past to study protein 
conformation via the stretching of the C=O bonding in the protein backbone within 
the amide I region (~1650 cm
-1
). It gives distinct spectral changes for the different 
protein structures. However, these regions also contain contributions from the amide 
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stretches arising from the N-acetyl groups of the GAGs. This technique can be done 
in an optically active manner as vibrational circular dichroism (VCD). VCD can be 
used to study protein conformation and has a major benefit of having no significant 
contribution from the GAG components [79]. However, VCD requires very large 
amounts of material and high intensity light to overcome its inherently weak signals. 
 
The GAG component of these studies can also be observed using several techniques. 
The most prominent and structurally useful of which is NMR. The signals 
originating from heparin have been fully assigned in NMR [30]. NMR has long been 
used to provide conformational information on polysaccharides and heparin, giving 
information on glycosidic linkages, sugar ring puckering and flexibility of the 
molecule [67,70,80]. NMR has been used within publications associated with this 
work only to characterise compounds and will not be discussed extensively. All 
NMR work was conducted in conjunction with Dr T. Rudd (Diamond Light Source), 
as part of ongoing collaborations.  
 
Another widely used technique for the study of GAGs such as heparin and HS is 
mass spectrometry. This technique is based around the calculation of mass to charge 
ratios from a sample often using the length of time it takes to move from the sample 
stage to a detector (time of flight), and from this the deduction of possible structures 
that could give rise to that size fragment. This technique has been used extensively to 
try and deduce sequence information from the sulfation pattern within heparin and 
HS samples and trying to link these to biological activities. It has so far yielded little 
insight into any sequence:activity relationships. Ion-mobility mass spectrometry has 
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been used previously to gain structural information on GAGs when binding cations 
[81].  
 
A technique that is currently being subjected to scrutiny for its potential to provide 
structural information on GAGs is Raman Optical Activity (ROA). This technique 
will be discussed in more detail in chapter 7 but, is of interest because it is thought to 
be directly sensitive to the overall conformation of complex GAGs such as heparin 
and HS in solution, under physiological conditions. This method is of particular 
interest because it is the only technique that directly reports the helicity of GAG 
molecules in solution, thereby giving some information on long range conformations 
[82]. 
 
In order to identify interactions of interest, the high throughput assay, differential 
scanning fluorimetry (DSF), has been used in this thesis extensively. This is a 
technique developed to study protein stability changes upon ligand binding [83], and 
has since been developed further to follow GAG binding to proteins [84,85]. DSF 
works through the binding of a hydrophobic dye to exposed aromatic residues within 
the protein as the protein is subject to a thermal degradation. The dye, SyproOrange, 
is self-quenching in an aqueous environment and, when stabilised by an interaction 
with the hydrophobic regions of the protein, usually buried in the core of a protein, 
and thus exposed when that protein unfolds, emits fluoresence at 610 nm, after being 
excited at 492 nm [83]. This technique can be carried out in a RT-PCR machine, and 
the fluorescence data are then analysed to discover the temperature at which the 
protein denatures. 
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The technique most extensively investigated within this thesis CD spectroscopy. The 
origins of the technique are based around an observation in 1895 concerning the 
optical rotation dispersion of an absorption band in samples, and were termed the 
“Cotton effect”. Eventually this led to the technique today known as circular 
dichroism, which exploits Cotton effects in samples to gain molecular information. 
The technique usually covers two main wavelength regions for structural protein 
work, far-UVCD (180 – 260 nm) and near-UVCD (250 -350 nm) for electronic 
transitions but, also strays into the IR for VCD, and also available is fluorescence – 
detection CD. Far UVCD is a spectroscopic technique that probes chiral 
chromophores in the backbone of proteins, providing information on the structure of 
the protein being observed through variations in their absorptive properties.  The CD 
arises from two circularly polarised components initially of equal magnitude, one 
rotating counter-clockwise (left handed, L) and one clockwise (right handed, R) 
which can be differentially absorbed by a chiral molecule, or a molecule that is 
placed in an asymmetric environment through ligand binding or other structural 
arrangements. A CD spectrum is reported as the difference in absorption observed 
between these two components, equation 1-1. 
 
1.1  ∆A = AL - AR 
 
These data are reported within this text in terms of millidegrees, and a representation 
is shown in Figure 1-8 on the next page. 
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Figure 1- 8: A representation of the circular dichroism effect at the point of 
interaction with a sample. In A, both left and right-handed circular polarised 
light (blue arrows) are absorbed equally resulting in zero bias towards either 
vector. In B the absorption of right circularly polarised light is higher than left 
circular polarised light and therefore the sum of these absorptions results in 
the vector being rotated to the left by X millidegrees, giving rise to the 
millidegrees units commonly used for CD spectra. 
 
The method of collection for the equipment at the purpose built CD beamline (B23, 
Diamond Light Source, Harwell, UK, synchrotron radiation circular dichroism, 
SRCD) is one of modulation between the L and R polarised light, rather than the 
alternatives of subtraction. CD as a technique is complementary to high-resolution 
NMR. CD can be carried out rapidly, a good quality spectra can be obtained <30 
minutes, and only requires small amounts of material for far-UV work (~0.3 µM 
concentrations, for a 15 kDa protein in a 0.02 cm path length cell).  
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The far UV region (180 – 260 nm) is sensitive to average secondary structures within 
proteins. It is able to distinguish between -helix, -sheet (parallel and anti-parallel), 
 - turns and unordered structures. There are two principal contributions to the 
spectrum originating from the peptide bond. There is a weak, broad n  π* 
transition centered around 220 nm and a more intense π  π* transition at 190 nm 
[73].  The transitions for the -helical spectrum were assigned in the 1960’s. They 
were taken to be an n1  π* transition, between 210 – 230 nm, and observed 
experimentally at 222 nm (negative sign). There are transitions predicted at 198 nm 
but observed at 206 nm (negative sign) for a πo  π* transition of parallel 
polarisation and also an associated perpendicular polarised transition at 191 nm, 
observed at 190 nm (positive sign). There was also a predicted transition, not 
observed at that time at 185 nm again from a πo  π* of a negative sign [86,87]. The 
transition at 222 nm originates from the promotion of an electron from the oxygen 
non-bonding atomic orbital to an antibonding molecular orbital involving oxygen, 
carbon and nitrogen [87]. The transitions at 206 and 191 nm result from the splitting 
of a single absorption band [87]. 
 
There are several definable far UV contributions from the different secondary 
structures summarised in Table 1-5. The contributions from -helical proteins 
consist of negative contributions at 222 and 208 nm, and a sharp positive band at 193 
nm. -sheet has a broad negative contribution at 218 nm and a positive feature at 195 
nm, while disordered proteins assignments are given as 217 (positive) and 200 
(negative) nm. The assignments of feature positions for proteins structures are taken 
from Greenfield [88]. The assignment for unordered structure however can be 
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difficult currently. As previously shown several proteins that are classified as 
unordered or have been denatured through different mechanisms actually have 
different CD spectra [89,90].  
 
Table 1- 5: A table summarising some feature positions for some basic 
protein structures in the far UV (180 - 260 nm) CD as stated by Greenfield 
[88]. 
Structure Feature Position Sign Notes 
-helix 193 nm 
208 nm 
222 nm 
Positive 
Negative 
Negative 
Strong, Sharp. 
-sheet 195 nm 
218 nm 
Positive 
Negative 
 
Broad 
Unordered 200 nm 
217 nm 
Negative 
Positive 
Strong 
Weak, Broad 
 
There can also be a contribution from amino acid side chains in certain 
circumstances [91,92]. There can be a positive band at ~224 nm for aromatic side 
chains, while sulfur containing side chains have a weak negative band at ~228 nm 
[93]. A study using small helical peptides found that tryptophan contributed a 
negative induced CD band at 222 nm (the point of a significant negative feature in -
helical proteins) and a positive one for tyrosine [92]. These contributions can affect 
secondary structural analysis, of which there are several widely used algorithms.  
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The sensitivity of CD data to protein structure has been known since the technique 
was first developed in the 1960s [87,94] and the theory of the origins of signals has 
led ultimately to algorithms that can predict protein secondary structures [95,96]. 
These include SELCON, CDSSTR, and CONTIN amongst others [97]. In this work 
the dedicated software CDNN (Version 2.0) has been used due to the ease of use, 
availability, suitable reference set of proteins, which include some proteins that have 
been used throughout this PhD project, and through manufacturers information [98].  
 
While these algorithms are sensitive to small changes within a protein structure, 
especially regarding the -helical content to which CD is particularly sensitive: these 
algorithms are mostly based upon reference libraries that are taken from crystal 
structures where NMR structures are unavailable. This means that any absolute 
values for structures will inherit any mistakes in the crystal structure through crystal 
packing or inherent from the conditions to which the proteins are subjected to during 
crystallisation. This is especially apparent for disordered structures, which, through 
their inherent flexibility, are generally difficult to crystallise. These algorithms tend 
to require detailed information on protein conditions such as path length and the 
exact concentration for the correct prediction of structure. Recently, however, the 
need for precise knowledge of concentration has been reduced, following 
development of an alternative scaling method for the prediction of -helical content 
[99]. The far UVCD spectra of protein-heparin complexes do contain contributions 
from heparin. However, these are negligible in comparison to the signal from the 
peptide bond so can be discounted from the analysis. The first observations of this 
kind were in the 1960s when oligosaccharides were investigated, giving a CD band 
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at 210-212 nm, assigned to the π  π* transition of the 2-acetamido group [95,100]. 
The technique has been utilized to investigate the structure of heparin in recent times 
along with complementary techniques [68]. While the contributions from heparin 
overlap with peptide bond signals and the technique, as a whole, is a low-resolution 
structural technique, nevertheless, it does allow the structural study of proteins in 
solution in the presence of heparin with relative ease. The technique is also carried 
out under physiological mimicking conditions and allows for dynamic processes to 
be observed in solution and so potentially contains considerable structural 
information, especially if used in conjunction with other complementary techniques. 
 
The near UV region (250 – 350 nm) is sensitive to the aromatic amino acids. These 
amino acids have characteristic regions where they exhibit a maximal signal. 
Phenylalanine exhibits weak bands between 255 and 275 nm, tyrosine between 275 
and 282 nm with a shoulder appearing at longer wavelengths. The strongest 
contributor to this region is tryptophan, which has a maximal signal at ~290 nm. As 
these signals derive from individual amino acids, the signal intensity for each band is 
entirely reliant on the amino acid sequence for each protein. The shape of these 
features and their amplitude also depends on their local conditions such as H-
bonding, position in the protein (buried or exposed to solvent) and any molecules 
that may affect their electronic properties (generally within 1 nm).  
 
Synchrotron radiation CD (SRCD) was developed in the 1980s [101,102] and has 
many advantages over benchtop CD instruments. The basis of these advantages lies 
in the increased photon flux that is available in SRCD [90], over 1000 fold increase 
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in intensity below 200 nm when compared to xenon arc light sources [73,103]. This 
increased flux provides several benefits. The SRCD light sources provide brighter 
light, especially at lower wavelengths (< 200 nm) where bench top CD instruments 
with Xeon lights begin to lose their intensity. This brighter light results in higher 
signal to noise ratios, providing several advantages; less material may be used to gain 
the same quality spectrum as normal CD, the same quality spectrum may be achieved 
in less time (approximately 10% of the time [90]) and also using the same quantities 
of protein as a standard bench top CD machine, higher quality spectra may be 
obtained, allowing for the observation of subtle differences to be measured 
accurately.  A SRCD source can reach wavelengths as low as 140 nm [90] for 
dehydrated samples and 168 nm for aqueous solutions, which enables a better 
differentiation between types of -sheet and other structures, especially unordered. 
Module B at B-23 (Diamond Light Source Ltd.), the equipment used for the CD 
work within this thesis, allows measurements between 165 and 650 nm. It also has 
several other advantages, both over other CD beamlines and benchtop CD 
instruments. It has a temperature controlled sample holder (5 – 95 °C), automated 
scripts and a variable beam size as small as 0.25 mm
2
 [104]. The small beam size has 
the added benefits of a high photo flux density (75 X10
11 
photons s
-1 
at 200 nm) and 
also allows the measurement of long path length cells (up to 10 cm) while 
maintaining a low volume [104]. 
 
These increased wavelength ranges (down to 168 nm) have great advantages when 
obtaining structural information on proteins. It has been shown to improve structural 
analysis of proteins in comparison to their crystal structures [105] and is possible in 
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aqueous solutions [106]. It has been shown that below 190 nm, SRCD has a large 
advantage in terms of signal to noise in comparison with benchtop CD instruments 
[107]. In this body of work the wavelength range generally employed will be 185 nm 
– 260 nm.  
 
1.5. Aims and scope of work covered by this thesis. 
 
As stated in this introduction the study of proteins:GAG interactions is a challenge 
that has not yet been met, and the aim of this body of work will be twofold, firstly 
CD, a technique capable of studying protein:ligand interactions in solution through 
the detection of protein average secondary structural changes, will be improved 
through either data analysis methods or the improvement of methodology in the 
collection of data. Secondly, new methods in addition to standard near and far 
UVCD shall be developed for use in the study of protein:GAG interactions. Whilst 
the aim is to achieve these two goals primarily, any additional information that can 
be gained investigating relevant biological systems of interest will also be of interest 
to the field and as such systems used have been selected based on their cost 
effectiveness and their interest to the field.  
 
The work in following chapters will comprise of these themes: 
 
Chapter 3:  This chapter, using the amyloid forming protein Hen egg white lysozyme 
(HEWL) looks into the effect of Zinc Chloride ions on the interaction HS with the 
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protein, utilizing little used denaturation techniques to differentiate apparently 
similar complexes.  
 
Chapter 4: Employs the interactions observed in chapter 3 and also an example of 
super oxide dismutase 1 (SOD1) with a non-GAG ligand to demonstrate the potential 
of using magnetic circular dichroism (MCD) in the study of protein:GAG 
interactions.  
 
Chapter 5: AT, the important protein within the blood clotting cascade, will be the 
focus of this chapter. A range of heparin like, and heparin based, polysaccharides 
will be tested for activity against anti factor Xa with the classic pentasaccharide as a 
positive control. Again underused denaturation techniques are employed to 
differentiate complexes. 
 
Chapter 6: This takes SRCD data from chapters 3 and 5 and applies generalised 2D 
correlation techniques to add resolution and information to the data already attained. 
 
Chapter 7: This chapter presents two improvements to data handling, specifically for 
the handling of ROA data regarding baseline correction and the normalisation of CD 
data before further processing. 
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Chapter 2: Materials and methods. 
 
2.1. Materials. 
 
Hen egg white lysozyme was obtained from Fluka, (Sigma-Aldrich, Gillingham, 
Dorset, UK). Heparin used is from porcine intestinal mucosa, stored as a powder 
(Celsus Laboritories, Inc. Lot- PH-42800 activity (anti-Xa) 201 IU/mg). Heparan 
sulfate, sodium salt from bovine kidney, was obtained from Sigma-Aldrich 
(Gillingham, Dorset, UK). Super-oxide dismutase 1 was expressed in E.Coli BL21 
and kindly donated by Dr G Wright (University of Liverpool, UK). 5-flourouridine 
was also kindly donated by Dr G Wright (University of Liverpool, UK). Fibroblast 
Growth Factor proteins were expressed in E.Coli BL21 cells, donated kindly by Mr 
Y Lee (University of Liverpool, UK). Resin used for antithrombin purification is the 
matrix from a HiTrap heparin affinity column.  
 
2.2. Methods. 
 
2.2.1. Synchrotron Radiation Circular Dichroism (SRCD): Basic set up and far 
UV SRCD. 
 
What follows is an overview of standard conditions used during a SRCD experiment 
on B-23, the details of which will be presented in each individual experiment since 
the conditions vary depending on the sample used and experiment performed. 
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A standard SRCD experiment to probe protein secondary structure would be 
conducted between 185 and 260 nm when in the presence of NaCl.  
 
When undertaking all spectroscopic experiments, thought must be given to the Beer-
Lambert rule in equation 2-1: 
 
2.1: A = L  c 
 
Where A= absorbance, L=path length (cm
-1
), =molar absorption of molecule at 
wavelength (L·mol
-1
·cm
-1
) and c = concentration (mol·L
-1
). 
 
To attain the ideal recording conditions, the detector voltage must be kept below 600 
mA whilst maintaining a high signal to noise ratio. To achieve these conditions in an 
experiment, three properties can be altered (within the setup available at B23), path 
length, concentration, and integration time.  
 
Integration time refers to the amount of time (in seconds) spent recording one data 
point at a single wavelength. The path length is distance in the sample through which 
light passes before the detector, usually measured in cm, and the concentration refers 
to the Molarity of the sample in the light path. The CD signal amplitude can be 
calculated via the number of amino acids present in peptide, since the main 
chromophores being probed at the wavelengths (180-260 nm, far UVCD) is the 
peptide bond (see Chapter 1.4).  
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Standard cells available for experiments range from 0.01 mm to 0.5 mm CaF2 and 
0.2 mm to 1 cm quartz cells. The path length of cells are nominally marked but 
accuracy decreases at the shorter length. The actual path length can be measured by 
utililising the interference waves in a Fourier transform IR instrument. A standard 
concentration in a 0.02 mm CaF2 cell with a 15 kDa protein would be around 0.5 
mg/ml. Two common buffer systems used for CD work are 12.5 mM (NaCl) PBS 
and 20 mM phosphate buffer. In order to obtain structural data below 190 nm a 
buffer low in absorbing chromophores must be used. This especially applies to 
concentrations of Tris and chloride which in particular are not tolerated, as they 
absorb UV light in the region below 200 nm, leading to a poor signal to noise ratio. 
A standard secondary structural experiment consists of an average of 4 scans, in 
order to reduce noise in the spectra. The benefit of N scans is the reduction in noise, 
which is related to the square root the number of scans (See Equation 2.2). There are 
limitations to the benefit of additional scans, however, as UV light is known to 
degrade proteins, and takes longer to acquire, so a compromise must be found. 
 
2.2: ns 
 
n = signal to noise ratio is proportional to the number of scans, s = scan number 
 
The standard equipment setup on module B at B-23 would be 0.5 mm slits and 1 
second integration time, at 20°C. 
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2.2.2. Near UV SRCD. 
 
Conducting SRCD experiments in the near UV region (250 – 310 nm), that probes 
aromatic compounds within a sample requires different experimental conditions to 
optimise data acquisition. There are several problems and benefits to this region of 
the spectrum in comparison to a standard far UV experiment (section 2.2.1), while 
the main drawback of the signal from aromatic side chains is their low abundance in 
comparison to the chromophore for far UVCD. To counter this, a longer integration 
time, increased path length and higher concentrations can be used. This region of the 
spectrum does not contain information on secondary structures of the protein. 
However, one advantage of this type of spectroscopy is its tolerance for salt, which 
does not absorb in this region, and the energy levels of the light involved at these 
wavelengths are lower (Equation 2.3) - meaning that UV damage to protein samples 
is not usually a consideration. Another benefit, relevant to the majority of work 
undertaken here, is that GAGs do not have a contributing signal at these 
wavelengths. This being noted, it is usual to use the same buffers, so that 
complementary far UV experiments maintain consistent experimental conditions. 
 
2.3: E=h 
 
E =energy (J), h =Planck’s constant (6.62606957×10−34 J),  = frequency (s-1) 
 
A standard near UV experiment would have a 0.5 mm slit, 3 second integration time, 
1 cm quartz cell and 0.5 mg/ml concentration of protein.  
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2.2.3. Degradation of proteins via far UV SRCD. 
 
UV degradation is conducted in the far UV region, in the same conditions outlined 
within section 2.2.1, however, many more scans are required in order to degrade the 
protein, and each scan is taken individually through the series. A typical experiment 
would require between 20 and 30 scans to achieve the desired degradation, which 
typically equates to around 2 hours exposure to the high intensity high photon flux 
radiation available at B23 (2 x 10
13
 photons s
-1 
mm
-2 
[108]). The number of scans 
required can depend on how sensitive each individual protein is to UV degradation 
and exposure can be adjusted by reducing slit width and integration time. 
 
2.2.4. Degradation of proteins through a thermal gradient within SRCD. 
 
A temperature series is stipulated between the regions of interest, and can be 
controlled in 0.1°C steps. When conducting these experiments, controls or 
consideration must be given to the effect that continuous exposure to UV light can 
have on the sample, as described in section 2.2.3. Typically a temperature series 
involving 5°C steps are employed. Each temperature is held for two minutes before 
data collection commences and the next step is begun. The temperature is controlled 
via a Peltier temperature controller (Quantum Northwest, Liberty Lake, USA). This 
can be controlled either manually or via the use of a script that can be incorporated 
into the OLIS™ data collection software. This system pumps water into the cell 
holder and the temperature is changed to the appropriate value. This then heats the 
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cell and sample within. Allowing adequate time for this process is essential for 
accurate results.  
 
2.2.5. Magnetic circular dichroism. 
 
The experimental setup at B23 can be modified in order to employ MCD. There is 
one major change to the equipment, the addition of a 1.4 Tesla magnet (permanent 
magnet for MCD, OLIS, Bogart, USA) sample holder in place of the Peltier 
temperature controller. The dimensions of this sample holder restricts the user to 
using only 1 beam during the experiments and cells with 1 cm
2
 dimensions. 
Experimental design in the near UV (270-320 nm) must only account for the 
concentration of tryptophans within the samples as this is the major contributing 
factor to spectra in this region, for full details see Chapter 4. 
 
An experiment is conducted first using a non-magnetic control sample holder to 
record the full aromatic spectra, and then again in the presence of the magnet. The 
magnet is first orientated either N  S (in relation to the light from source to 
detector) or S  N and then reversed for the second recording. As this is done, it is 
important that all other possible variables are maintained, including the orientation of 
the cell in relation to the propagation of light. 
 
The MCD spectrum is then obtained by the removal of standard CD contributions via 
the deduction of the NS spectrum from the SN. This results in a 2 x MCD 
spectrum, which is then halved to give the MCD spectrum for the sample. A 
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background of buffer alone must be recorded as the buffer is not deducted during the 
above process, rather contains a induced drift, see Chapter 5, Figures 4-8 and 4-9 for 
an example of how this effects data.  
 
2.2.6. Differential Scanning Fluorimetry. 
 
DSF is a technique that can be used to survey large numbers of compounds for 
interactions with a target protein. It works on the basis of the dye SyproOrange 
binding to hydrophobic regions of a protein that become exposed as the protein 
unfolds from thermal stress.  Upon binding to hydrophobic regions of the protein the 
fluorescence 620 nm emission of SyproOrange, which is excited at 492 nm, increases 
[83].  This dye is only capable of detecting proteins with a hydrophobic regions, that 
is, globular proteins. This normally restricts use to those proteins with a molecular 
weight of 11 kDa and above.  
 
For each protein investigated it is standard practice to test a range of concentrations 
in order to attain a high quality, repeatable, melting curve for analysis with 
compounds present. A typical value for this type of experiment would be 10 µM for 
a 15 kDa protein. Preparation of the dye itself involves diluting the neat dye by 
adding 0.02 µl per 1 µl of fresh H2O (50 x working concentration). It can then be 
mixed with the buffer of choice for the experiment; this solution is at 10 x working 
concentration. The experiment is conducted in a 7500 fast PCR instrument ramping 
the temperature from 30 to 90°C in 0.5°C steps. At each point the temperature is held 
for 5 seconds before flouresence is recorded for 30 seconds. The fluorescence data 
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are then analysed by obtaining the first derivative of the curve for each sample well, 
giving the point at which 50% of the protein is denatured. These experiments are 
typically conducted as triplicate repeats of a single sample, which are then repeated 
again in triplicate, giving 9 readings from 3 independent samples. This ensures that 
standard deviations can be found and then used to find and significant differences 
using Student’s t-test (Equation 2-4). 
 
Equation 2-4: Independent two sample students t test, equal sample size equal 
variance: 
 
 
where 
s
x1x2 is: 
 
 
 
 
and the degrees of freedom for significance testing is defined as: 
 
 
 
Where x1 and x2 are the sample means of groups 1 and 2, s is the standard deviation 
of that mean and n the number of measurements in that group. 
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2.2.7. Changing the cation state of heparan sulfate and heparin molecules. 
 
In order to change the cation state of heparin and HS molecules, ion exchange resin 
(Alfa Aesar, Dowex 50W x8 200-400 (H), Lancs, UK) must be used. To do this the 
resin must be first put into either their H
+
 or cation form. 
 
Cation forms of HS were prepared from HS (10 mg/ml, in deionised water), shaken 
with cation-cation exchange resin, spun and the supernatant removed, quantified 
(Absorbance at 232 nm) and employed for experiments.  
 
2.2.7.1. Creation of H
+
 resin beads. 
 
1. Wash resin with H2O for 30 minutes 
2. Wash through a filter 3 times with a 1 M HCl solution 
3. Wash 3 times with H2O 
4. Check H2O elute below the filter is neutral with pH paper to ensure excess 
acid has been removed. 
 
2.2.7.2. Creation of resin in cation forms. 
 
1. Wash H+ form resin with H2O 
2. Incubate with 2 M chloride salt (eg zinc chloride ions), whilst stirring with 
magnetic stirrer. 
3. Wash through a filter 
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4. Wash with H2O to remove excess salt 
5. Repeat steps 2-4 to ensure complete coverage. 
 
2.2.7.3. Modification of heparin/HS cation state. 
 
1. Make a heparin solution of 10 mg/ml in H2O 
2. Add a spatula of the pre-made ion form resin beads (section 2.2.7.2) per each 
500 µl of heparin solution. 
3. Spin solution and remove the supernatant 
4. Recover the beads for re-use in section 2.2.7.1. 
 
2.2.7.4. Isolation of shrimp heparin compounds. 
 
Shrimp heparin (SH) was isolated via a homogenised shrimp head:acetone solution 
(10:4 v/v) for lipid removal, ground and dissolved in 1 M NaCl adjusted to pH 8.0 in 
preparation for a 24 h proteolytic digestion of the solution at 60°C, the result of 
which was filtered and the negatively charged components of the solution removed 
via ion-exchange resin. The resulting elute was precipitated with cold methanol at 4 
°C over 48 hours, filtered, and the precipitate collected. This was then subsequently 
fractionated using DEAE-sephacel. Full details of SH purification are provided in the 
Brito et al 2008 publication [109].  
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2.2.8. Purification of AT from human plasma. 
 
All following steps are completed at 4°C. All purification buffers contain 0.1 M Tris-
HCl buffer at pH 7 
 
1. Run 2 x column volumes of 0.02 M NaCl buffer on heparin Sepharose 
column. 
2. Load human plasma onto heparin Sepharose column (2 ml plasma for 5 ml 
column volume) 
3. Wash with 0.02 M NaCl buffer 3X column volume 
4. Wash with 0.5 M NaCl buffer 3X column volume 
5. Repeat steps 2-4 
6. Elute AT with 2.0 M NaCl solution. 
7. Concentrated with SpinX UF spin concentrator columns 30 kDa cut off at 
4°C 
8. Take 280 nm absorbance to check protein concentration. 
9. Confirm protein in SDS page gel. 
This method was developed by and completed at the University of São Paulo by Dr 
M. Lima as part of a collaborative project. 
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2.3. Data handling and analysis methods. 
 
2.3.1. Circular dichroism data handling. 
 
The raw data, were recovered from the Olis software as several spreadsheets. The 
data were loaded into the R statistical software package as a matrix. The scans were 
then averaged together to form the mean spectra across the data. The same was then 
done to the baseline spectra consisting of all components minus sample, i.e. cell, air, 
and buffer which is then deducted from the sample spectra. The resulting spectrum 
was then normalized to a value at the beginning of the spectrum where there are no 
chromophores and the data were set to zero. The normalisation of data has been to 
the average value between 250-255 nm as this was found to be more accurate than 
normalisation to 260 nm alone, this is described in Chapter 7. For near UV work 
spectra were normalized to 330 nm. 
 
All data handling was performed within R statistical programming software [110]. 
 
2.3.2. Estimation of protein secondary structure. 
 
Pre-processed far UVCD data were entered into the neural networks based software 
CDNN (V 2.1) [98]. Fits were considered reliable when the result was between < 
90% and > 110%. These structural estimations were checked against PDB structures 
where possible.  
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Chapter 3: A zinc complex of heparan sulfate destabilises 
lysozyme and alters its conformation. 
 
3.1. Introduction. 
 
3.1.1. Hen egg white lysozyme. 
 
 
Figure 3- 1: The crystal structure of HEWL (pdb number 4AXT) showing two 
exposed Trp  residues [black] in the carbohydrate binding cleft. 
 
HEWL is a small, well studied globular enzyme and has been the subject of over 
6000 articles since its discovery in 1922 [111]. It is highly conserved between many 
species and is expressed in the secreted fluids as an antibacterial innate defense in, 
for example, tears, milk and saliva. It is a muramidase that cleaves the glycosidic 
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linkage of carbohydrates, specifically the 1,4 beta linkage between N-acetylmuramic 
acid and N-acetyl-D-glucosamine in bacterial cell surface polysaccharides. HEWL is 
a 14.2 kDa protein consisting of 129 amino acids, with 4 disulfide bonds. The protein 
has two main domains, divided roughly along the axis of the active site cleft. The 
alpha domain (amino acids: 1-36 and 85-129) is helical, containing 4 helices, while 
the beta domain, which includes the central region of the primary amino acid 
sequence (amino acids: 37-84) consists of a three-stranded -sheet, a loop and a 
single helix [111]. The overall structure of HEWL is shown in Figure 3-1. HEWL is 
a protein that is susceptible to aggregation, an intrinsic property of many proteins 
[112]. HEWL became a major target for the study of protein aggregation since point 
mutations in it were discovered to be involved in hereditary systemic amyloidosis in 
1993 [111,113]. In general, the aggregation of proteins can lead to physiological 
problems, which include Parkinson’s disease (PD), Alzheimer’s disease (AD) and 
congestive heart failure. Aggregation has been proposed in both a beneficial role 
[114] and as a harmful process resulting in cytotoxicity arising from soluble 
oligomers, as opposed to fibrils [115,116].  It has been suggested that the folding of 
proteins into their active forms can take several routes to their resulting active 
conformations [117].  The formation of amyloid plaques has also been identified as a 
multiple phase process [118], while HEWL has been proposed as a paradigm for 
protein folding and misfolding [119], having its core structures of amino acid regions 
26-123 and 32 to 108 heavily implicated in amyloid formation [120]. The creation of 
amyloid fibrils involves the interplay of several factors. A key factor in amyloid 
formation is the native state stability of the protein [112], promoted by the presence 
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of  “seeds” [121] and this seeding is not confined to proteins of the same sequence 
[121,122].  
 
3.1.2. GAGs are associated with amyloid fibrils and are influenced by cation 
state. 
 
GAGs, in particular HS, are associated with the aggregation of proteins and are a 
consistent factor in amyloid plaque formation, regardless of disease and protein 
component [123,124,125]. It has been reported that HS is involved in the early 
formation of amyloid plaques, including those of AD and PD [126,127], and has also 
been proposed as an initiator of these plaques [125]. The scrutiny of GAGs due to 
their association with plaque formation [127,128] has led to the idea that the 
interactions between these sugars, widely expressed on mammalian cells and a ligand 
for many proteins [129,130], could be important for the formation, development and 
stability of the amyloid fibrils formed during these disease processes. GAGs 
themselves have been shown to alter conformation and activity when substitution 
pattern and cation state alters [45]. The binding of these cations can also be selective 
for particular HS structures [68]. In addition it is known that zinc ions selectively 
bind to heparin in a manner that is above that of just simple electrostatic interactions 
[131]. The conformation of heparin is known to change with the addition of metal 
ions, as shown by ion mobility mass spectrometry [45,81] and NMR [67,70,132]. 
The conformational change induced in heparin has led to work that showed examples 
of signaling and non-signaling determined solely on the cation state of the heparin in 
FGF systems [46]. One of the most in-depth studies of cation-heparin binding 
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involves copper ions, which are shown to specifically coordinate with heparin in a 
high affinity manner initially before a less specific binding takes place [68].  
 
Zinc (Zn) has been shown to have a variety of effects on amyloid diseases [133,134], 
and is the most abundant trace metal in the brain, varying between 0.15 and 0.20 mM 
in brain tissue. It has been reported that Zn ions bind to A peptides [135,136] with 
three histidine residues being heavily implicated in coordinating the binding of zinc 
to A [136].  Zinc is also reported to inhibit A toxicity at µM concentrations [137]. 
A complex of modified heparin:Zn ligands with HEWL showed some initial promise 
in the DSF [83,84] assay (data not shown), which measures the thermal stability of a 
protein indirectly by reporting the fluorescence emitted by the dye SyproOrange. 
SyproOrange is self-quenching in an aqueous environment, only emitting a signal 
when stabilised by aromatic amino acids, which are found commonly in the 
hydrophobic core of proteins. This metal ion was therefore studied using the natural 
ligand HS, as an investigation into the effect cation binding has upon the important 
HEWL:HS interactions, an important model amyloid forming protein. The following 
data will establish initially that there is an interaction between GAG compounds and 
HEWL in Table 3-1 through the use of DSF. This is then confirmed by far UV 
SRCD in Figure 3-2A and near UV SRCD in Figure 3-2B. The observed changes are 
confirmed to be stemming from HEWL-HS(Zn) and not Zn cations in Figure 3-3. 
The stability of the protein and complexes are investigation through temperature and 
UV degradation in Figures 3-4 and 3-5 before being further analysed in Figures 3-6 
and 3-7. The spectra in Figure 3-2A are analysed for secondary structure content in 
table 3-2. 
A zinc complex of HS destabilises lysozyme and alters its conformation. 
 53 
3.2. Results and discussion. 
3.2.1. Discussion of thermal stability investigations. 
 
Table 3- 1: The thermal stability of HEWL alone and in the presence of a 
ligand. HEWL at a concentration of 10 µM (0.14 mg/ml) in the presence of an 
excess of GAG, based where necessary on average molecular weight (Mw). 
The protein was subjected to a step-wise temperature gradient, from 32 °C to 
85 °C in 0.5 °C steps. There was an initial 2 min incubation period at 31 °C 
and 5 s between each temperature increase to allow equilibration. Data were 
collected for 30 s at each temperature. First derivatives of the melting curves 
were employed with the Solvitzky-Golay smoothing method, using a second 
order polynomial. 
Sample Melting Temperature 
HEWL 67.7 (±0.7)°C 
HEWL:ZnCl
2+
 72.1 (±0.3)°C 
HEWL:HS 65.3(±3.6)°C 
HEWL:HS(Zn)  57.6(±1.6)°C 
 
The initial observations using the DSF thermal stability assay (Table 3-1), 
demonstrated dramatic changes in the stability of HEWL. The presence of HS(Zn) 
with HEWL reduced the stability of the protein by 10.1°C (67.7 to 57.6 °C). This 
observation is not repeated by either HS alone (stability reduced by 2.4 °C) or by 
ZnCl2 ions that stabalise the protein by 4.4 °C. Altered stability induced by GAGs 
such as heparin or HS is not new, since stabilisation has been demonstrated 
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extensively in some FGFs [139,140], as well as in AT [141] (See Chapter 5). It is, 
however, unusual to see a destabilisation of a protein by HS, but here it is 
demonstrated that significant denaturation of HEWL by HS saturated with zinc ions 
(HS(Zn)) occurs, and this is unique to the zinc complex since HS alone has minimal 
impact on the overall stability of the complex. The Tm for the HEWL:HS complex 
has a large standard deviation (SD) from the mean (2.25 times higher than HS(Zn), 
the next highest SD), and this can be attributed to comprising a very heterogeneous 
mixture of potential ligands and, while it has not been subjected to ion exchange, it is 
predominantly in the Na form (according to the manufacturer). The HS(Zn) 
conversely might be strongly inclined to fewer possible conformations as the 
polysaccharide chain approaches saturation with Zn ions, and therefore would have a 
smaller deviation from the mean as the compound would become more 
homogeneous relative to that of unmodified HS. This hypothesis is further evinced 
by the NMR studies conducted on these samples (supplementary data, [142]) and it 
will not be discussed in detail here. However, in summary, it was shown that Zn ions 
bind preferentially to IdoA, possibly interacting with the carboxylic acid. There is no 
sign of conformational change along the chain; NOEs stemming from the glycosidic 
linkage region which does not change. These remained consistent in the presence and 
absence of Zn (NMR experiment design and analysis conducted at the Ronzoni 
Institute, Milano, by Dr T Rudd).  
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3.2.2. Discussion of SRCD investigation of complexes. 
A B
 
Figure 3- 2: Panel A: Far UV SRCD spectra (185–260 nm) of HEWL (0.50 
mg/ml) [blue], HEWL with HS (0.08 mg/ml) [red] and HS(Zn) (0.08 mg/ml) 
[black]. Panel B: Near UVCD spectra (250–330 nm) of HEWL (0.25 mg/ml) 
[blue], HEWL with HS (0.04 mg/ml) [red] and HEWL with HS(Zn) (0.04 
mg/ml) [black]. The Trp residues of the active site reportedly give rise to a 
peak at 291 nm and a trough at 293 nm [138]. 
 
These samples were then subjected to far UVCD (185 -260 nm) at Diamond Light 
Source, with the hypothesis that these complexes would yield different secondary 
structures. The results are shown in Figure 3-2A and the secondary structure evident 
from these spectra are shown in Table 3-2 as derived from the CDNN software [98]. 
As can be seen from these results, the structures induced by these ligands, with 
significantly different thermal stability profiles, are remarkably similar. There is a 
general loss of -helical content with an increase in antipararellel -sheet in both 
experiments involving HS ligands. HS and HS(Zn), interacting with HEWL results 
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in a loss of  18% of -helix, and are replaced by increases of 22 and 27% of 
antiparallel ß-sheet  respectively.  
 
Table 3- 2: Secondary structure of HEWL, HEWL:HS and HEWL:HS(Zn) as 
determined using the CD spectra in Figure 3-2 using CDNN version 2.1 [98]. 
Values given by software are presented in black while the difference 
compared to HEWL alone are presented in red text. 
 
 HEWL HEWL:HS HEWL:HS(Zn) 
Helix 27% 9% 
(-18%) 
9% 
(-18%) 
Antiparallel 12% 34% 
(+22%) 
39% 
(+27%) 
Parallel 7% 4% 
(-3%) 
4% 
(-3%) 
-Turn 23% 20% 
(-3%) 
18% 
(-5%) 
Random Coil 33% 34% 
(+1%) 
31% 
(-2%) 
Total Sum 100% 100% 102% 
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As these complexes were similar in secondary structure, the surface interactions were 
probed in Figure 3-2B by near-UVCD. This area of the CD spectrum relates to 
transitions observed in the aromatic residues of the protein, and in this case has a 
particular wavelength (peak at 291 nm and a trough at 293 nm [138], the spectra here 
slightly disagree due to different buffer conditions which can change the local 
environment of the chromophore and therefore the peak position) which previously 
has been associated with the two (of six) Trp residues within the active site (Figure 
3-1) [143]. The data presented in Figure 3-2B indicate that, even though again 
similar, there are differences in the mode of binding of the HS(Zn) ligand in and 
around the binding site when compared with standard HS, which is in combination 
with other possible binding sites elsewhere on the surface of the protein. The 
interactions with Trp are investigated further in Chapter 4 by MCD.  
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Figure 3- 3:Far UV SRCD spectra (185–260 nm) of HEWL (0.50 mg/ml) with 
either zinc cations (ZnCl2) (at equimolar ratio of typical HS cation content, 
red) or with HS(Zn) (0.08 mg/ml, black).  
 
Zinc itself is not the cause of the structural changes in HEWL (Figure 3-3), nor the 
stability difference as shown in Table 3-1. Figure 3-3 shows the effect of Zn ions on 
the conformation of HEWL and, as can be observed, is distinct from that of 
HEWL:HS(Zn), demonstrating that it is the combination of HS with Zn that is the 
cause of the observed effects.  
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Figure 3- 4: Exposure of HEWL and HEWL:HS (HEWL 0.5 mg/ml, 
HS/HS(Zn) 0.08 mg/ml) complexes to a temperature gradient (A–C). The 
temperature ranged from 10 to 85°C in 5°C increments (progressively blue to 
red) resulting in distinct thermal denaturation profiles.  
 
 
Figure 3- 5: Exposure of the HEWL and HEWL complexes to prolonged UV 
irradiation resulted in denaturation. The stability of complexes of HEWL alone 
(A) with HS(Zn) (B) and native HS (C) to degradation by UV radiation was 
followed over 60 scans between 180 and 260 nm (experimentally, only 185 – 
260 nm are plotted), which can detect the changes in secondary structure 
produced by UV-induced denaturation. The red line indicates the starting 
spectrum, proceeding progressively to blue.  
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Further ways to distinguish similar complexes involve the degradation of the protein 
in the presence of ligands through either UV irradiation or thermal degradation 
(Figures 3-4 and 3-5).  The raw data of these types of experiments can be difficult to 
interpret therefore principal component analysis (PCA) has been applied to them. 
PCA, (used in chapters 3 and 5 on lysozyme and antithrombin proteins complexed 
with GAGs) is a mathematical technique designed to simplify complex data sets. The 
analysis technique allows features which differ between spectra to be revealed, 
which in complex data set may be impossible by eye. This allows for patterns, 
groupings and kinetic vectors to be revealed, thus adding information to the basic 
spectra recorded. The result is a list of weighted principal components (PC) that 
explain a percentage of variance in the data. The weighting of the PC is termed the 
loading, and these can be plotted in scree plot and the most important PCs chosen for 
plotting. The original dataset, V, can be described by the summation of loaded 
contributions (wn) from the various PC's (Pn) and the remaining variance stemming 
from noise, e, thus: 
 
V = w1.P1 + w2.P2 + w3.P3 + … + wn.Pn + e 
 
By analysing data in this way, the resulting data stem from two key points, firstly 
that no assumption is made and secondly that each PC is independent of all other 
PCs and complex data sets can be reduced to just a couple of variables which explain 
a majority of the variance in the data observed.  
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By applying this technique to the data in Figure 3-5, differences in the pathways 
taken by each sample can be observed, especially in this instance between the 
thermal degradation of HEWL in Figure 3-4A, compared to the two examples in a 
complex with the HS ligands (Figure 3-4B and 3-4C). This demonstrates that for 
HEWL there is a two step process centered at 65°C, while the samples containing HS 
and HS(Zn) show continuous degradations. The data presented are further 
investigated by the variable reduction technique, PCA in Figure 3-6.  
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Figure 3- 6: Principal component analysis (PCA) of the SRCD spectra of 
HEWL and HEWL:HS complexes undergoing thermal denaturation (Figure 3-
4). The colours progress from blue (10°C) to red (85°C) 
 
The PCA analysis of the temperature degradation, shown in Figure 3-6 further shows 
the difference in stability and through the two stage unfolding of HEWL alone 
(squares), confirming the DSF investigations, with a major transition of 
conformational states occurring at 65 °C. The two examples with ligands are again 
similar when utilizing these two principal components but, interestingly, they both 
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lose the two-step degradation, rather, exhibit a more directed kinetic pathway to 
similar endpoints. This pathway is subtly different between the two ligands 
indicating a different interaction in each case.  
 
Figure 3- 7: PCA of the far UV SRCD spectra of HEWL and HEWL:HS 
complexes undergoing UV denaturation shown in Figure 3-5. HEWL, free 
and bound, undergoes a gradual denaturation when exposed to UV radiation. 
The process is linear with two components describing the event. The plot 
progresses from scan 1 (red) to 60 (blue). 
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All three systems appear to be equally susceptible to UV degradation (PCA, shown 
in Figure 3-7) and each have the same route towards their endpoints with equal 
additions of component 1, and equal losses of component 2 in each case. This PCA 
plot does, however, highlight the structural differences between the three samples 
even though quantitative structures cannot be deduced from these data. The alteration 
of temperature degradation (and DSF results) but not the UV irradiation result for 
HS(Zn) suggests that the binding of the HS(Zn) ligand increases the accessibility of 
the hydrophobic regions of the protein to the surrounding buffer through a 
conformational change. It can be suggested that, owing to the consistency in the 
stability of the proteins to UV irradiation, the core structure remains intact in each 
case, suggesting that the zinc form of HS is affecting the surface only. This could 
lead to a more flexible surface structure capable of adopting several conformations 
that may be more susceptible to binding other proteins – especially if hydrophobic 
regions of the protein become exposed to the buffer. The UV degradation data 
presented here are further investigated in the chapter covering data analysis (Chapter 
6). 
 
3.2.3. General discussion of results. 
 
Here, it has been shown that a complex of HS and HS(Zn) bind to a model amyloid 
forming protein, HEWL, altering its secondary structure to that resembling a non-
cytotoxic amyloid complex of heparin and apomyoglobin at pH 5.5 [114]. This 
structural change consists of a large loss of -helical content, replacing it with -
sheet. It can be hypothesized that these structural changes are taking place within the 
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 domain, as this is the domain that contains the majority of -helices in HEWL 
[111]. This  domain contains 2 of 3 predicted amyloid forming hotspots (by 
hydrophobic cluster regions) [111,144]. The greater flexibility of the surface could 
open up the core elements of HEWL for further interactions, these core elements 
(amino acids 26–123 and 32-108) have been identified previously as being core 
structures in lysozyme amyloid formation [120]. The far UVCD spectra induced by 
HS and HS(Zn) also closely resemble amyloid HEWL created using high 
concentrations of ethanol [145]. The folding/unfolding of HEWL is known to be pH 
dependent [111] and, in acidic conditions the  domain unfolds first, followed by the 
-domain [111,146]. The stability of HEWL is also known to change dramatically 
with pH, especially at lower pH’s (several studies summarised in Figure 3-7 [111]). 
This property was known early on; in 1976 it was said that ‘charge balance in a 
protein plays an important role in maintaining its conformation’ [147], and this could 
be the situation being observed here. HS and heparin are two of the most negatively 
charged natural molecules, de-N-sulfated heparin having a pI between 1 and 3 
[148].When these molecules bind to proteins the properties of the protein within the 
complex could be changed via the alteration of the pI, thereby something that was 
initially stable at higher pH’s would now have altered surface charges due to the 
combined effect of its positive charges becoming involved in electrostatic binding 
with the negatively charged HS or HS(Zn) and the presence of a negatively charged 
polysaccharide. This altered pI would then be more susceptible to destabilisation and 
conformational change at pH values at which it was initially stable. Therefore 
HEWL, which has a natural pI predicted to be at 11.35 [149], could conceivably 
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become unstable at physiological pHs when bound to the negatively charged HS, 
shifting its pI towards the acidic. 
 
There are several hypotheses that could be tested in future work following from this 
study. Firstly, the mode of binding in the active site could be investigated to confirm 
whether the HS and HS(Zn) ligands are indeed binding in subtly different ways. This 
has been attempted via MCD in Chapter 4. MCD is a method capable of selectively 
observing Trp residues. Another potential method is the observation of the protein in 
near UVCD (250-310 nm), NMR or by tryptophan fluorescence after the blocking of 
Trp with an organic reagent as described by Ladner et. al. [150]. Secondly, the pI of 
the complex could be tested with simple absorption at 600 nm to obtain the optical 
density of a solution containing lysozyme across a pH range, and compared to the 
results in the presence of a heparin/HS ligand. Another way to test the pI of 
complexes would be with isoelectric focusing. In order to do this, the protein would 
need to be crosslinked to the heparin/HS ligand via EDC or another crosslinking 
method to avoid the high current involved causing disassociation of the protein from 
the ligand. 
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Chapter 4: Magnetic Circular Dichroism as a technique to 
study tryptophan:ligand interactions.  
 
4.1.1. Introduction to MCD. 
 
MCD is a technique arising from Faraday’s observation in 1846 that the plane of 
polarised light rotates when subjected to the poles of an electromagnet [151,152]. 
These differences in optical rotation (OR) only occur when subjected to a 
longitudinal magnetic field, one that is in the same direction as the propagation of 
light along the Z-direction. When measured at wavelengths in which a chromophore 
from the sample absorbs this then gives rise to MCD. The Magnetic Optical Rotation 
(MOR), which is the rotation of polarised light through a sample in the presence of 
an applied magnetic field, and MCD signals are additive to the natural OR and 
standard CD within a sample, and the strengths of both are in direct proportion to the 
magnetic field applied to the sample. This means that when Hz (H – the magnetic 
field, along the Z axis) equals zero, then the MOR and the MCD also equal zero. 
Natural OR results from very low symmetry within a sample leading to a difference 
in the refractive indices of the sample to left and right polarized light. The angle of 
rotation of polarised light propagated though a transparent material (a protein in this 
work) and magnetic field is described by equation 4.1: 
 
4.1:  = VBd 
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This is where  is the angle of rotation in radians, V is the Verdet constant for the 
material (rad T
-1
 M
-1
), B is the strength of the magnetic field in the direction of the 
light propagation (in Tesla) and d is the path length where the light, sample and 
magnetic field interact (in meters). This effect is shown in Figure 4-1. 
 
 
Figure 4- 1: A schematic illustration of the origins of MOR, the principle on 
which MCD is based. The letters refer to parameters in Equation 4-1. The red 
arrows refer to the direction of the polarised light as it is altered by passing 
through the magnetic field. 
 
In MOR a substance with a positive Verdet constant would undergo a L-rotation 
(anticlockwise, relative to the observer facing the light) when the direction of 
propagation is parallel with the magnetic field. In the presence of a magnetic field 
anti-parallel to the direction of propagation a R-rotation occurs (clockwise). 
Therefore if light is passed through a sample in these conditions and then reflected 
back through the sample the rotation is doubled. In our experimental set up this is 
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achieved through the reversal of the static magnet employed to reverse the 
orientation of the poles relative to the propagation of the light. 
 
MCD differs from MOR in that it occurs, like conventional CD, only where an 
appropriate chromophore absorbs, while MOR is observable at all wavelengths. 
MCD differs from conventional CD in that the signals rely on the splitting of ground 
and excited states of chromophores by an applied magnetic field. MCD has three 
potential contributions (components) that arise from three separate possible electron 
states, referred to as components A, B and C. The MCD signals observed in the near 
UV arise form components A and B, they originate through π  π* transitions, with 
fine detail added to the features by the 
1
Lb vibrational transitions at 292 and 286 nm, 
and the negative feature at 275 nm is associated with the 
1
La band [153,154]. The 
transition exists in a triply degenerate excited state, within which the angular 
momentum of the electrons change depending on the local environment [155,156]. 
With no magnetic field present, the net moment is zero. However, when a magnetic 
field is applied, these are then split into each of the 3 states. This means that 3 
different transitions x, y, z are now possible and no longer cancel each other out as 
the refractive indices to circularly polarised light (+ and -) are unequal.  These 3 
transitions can be observed as the 3 components, A, B and C. (Components A and B 
shown in Figure 4-2). Component C is temperature (1/T) dependent [155] and can be 
isolated through a temperature gradient, it is also the weakest contributor. It will not 
be considered within this work, which involves organic biological molecules under 
or close to physiological conditions, because it originates in a paramagnetic ground 
state in free radical containing species or metal ions. 
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The magnetic transitions observed in MCD arise from the different energy levels set 
up by the Zeeman effect on the electron orbitals and result in components A and C. 
In component A the orbitals of the excited states become split into a higher and 
lower energy state that interact differently with left and right polarised light. In 
component C the ground states of these electrons are split, in a manner that is 
directly proportional to the inverse of the temperature, and thus can be differentiated 
from other components via a temperature gradient. The B component is one in which 
two separate excited state orbitals have energy levels very close to one another which 
allows mixing of the states. Components A and B are shown in Figure 4-2. 
 
 
Figure 4- 2: Schematic of the split electron energies as a result of the 
Zeeman effect, in the presence of a magnetic field, giving rise to a A and B 
components in MCD spectra. 
 
 
 
 
 
 
MCD as a technique to study tryptophan:ligand interactions. 
 71 
4.1.2. MCD in the near UV (270 – 350 nm). 
 
A standard MCD spectrum in the near UV (270-350 nm) of a protein will typically 
contain 5 contributions. The signal arising from tryptophan (Trp) is by far the most 
significant. It gives rise to the only positive features by any amino acid in the near 
UV, making it distinctive [156]. The Trp features comprise a sharp positive feature 
between 292 and 295 nm (∆EM = 2.35 M-1 cm-1 T-1), a positive shoulder at 284 nm 
and a broad negative feature with a maximum at 267 nm. Other contributors in this 
region are from phenylalanine (Phe) and tyrosine (Tyr). The contribution from Phe is 
via a weak, negative feature at 267 nm (∆EM =  -0.055 M-1 cm-1 T-1) and Tyr, which 
exhibits a stronger band, comprising a single minimum negative feature at 275 nm 
(∆EM =  -0.38 M-1 cm-1 T-1). It has been shown in previous studies that TRp 
quantification can be achieved through measurement of the maximal peak value at 
the feature between 292 and 295 nm [154,157,158]. It has also been observed that 
this feature can move between protein samples, so locating the maxima is essential 
[154]. The shift in the feature observed at 292-295 nm demonstrates, to some extent, 
that Trp residues are sensitive to their local environment [154,159]. Other evidence 
for this sensitivity comes from a small shift in peak position which can be observed 
by changing the solvent, and a consistent blue shift of the positive spectral feature to 
292.1 nm when the protein becomes unfolded [154]. The Tyr feature at 275 nm 
gradually red shifts as the pH increases as the chromophore becomes ionised (pK tyr 
~10.1), up to a maximum of 292 nm [154,157]. This can be exploited for the 
determination of Trp:Tyr ratios within a protein [160]. The local conditions of 
tryptophan have been utilized in the observation of quaternary structure in 
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heamoglobin using bands at 292 nm and 286 nm [161], and also on the same protein 
for time resolved MCD study of a hydrogen bond formation [162]. The technique has 
also more generally been used to study a wide range of proteins containing metal 
ions, especially haem groups [163].  
 
Artifacts can appears in MCD spectra with distortions to the direction, strength and 
focal point of the applied magnetic field between samples. Alternatively artifacts can 
arise from changes in the beam position relative to the magnetic field giving rise to 
much the same effects. These issues cannot occur with spectra obtained in this body 
of work owing to the use of a static, permanent magnet (i.e. not an electromagnet) 
and the precise optical benches employed to stabilise the beam on B23 at Diamond 
light source. Any signals arise directly from the interaction of light between the 
sample and the magnetic field.  
 
Since it has been shown previously that Trp residues can be sensitive to their local 
environment [161,162], and the main MCD feature has been used to identify ligand 
binding [162,164], it was proposed to investigate whether this technique was suitable 
for the observation of GAG:protein interactions with specific Trp residues.  
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4.2. Results. 
Initially, it was confirmed that the MCD signals observed between 250 and 350 nm 
are features that arise from observing the Trp amino acid. This is demonstrated in 
Figure 4-3. 
4.2.1. Free Trp amino acid signal in MCD and its sensitivity to environmental 
changes. 
 
Figure 4- 3: MCD spectrum (250-350 nm) of tryptophan amino acid (14.8 
µg/ml / 71 µM, PBS). Averaged over 4 scans, 1 cm path length, 1 second 
integration time, 1 mm slit, 1.5 T magnetic field strength. 
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This spectrum (Figure 4-3) is similar to a spectrum of tryptophan reported in the 
literature. Trp residues indeed exhibit a strong MCD spectrum in the near UV [158]. 
There are 3 features present, as reported in the literature, and these are thought to 
arise from two transitional modes. The large negative feature at 270 nm and the 
positive 292 nm feature form a B component contribution while, the harder to define, 
positive shoulder at 286 nm is thought to originate from an A component. The main 
positive feature at 292 nm has previously been used when quantifying protein 
concentration in solution [154,155,157,158,159] and has also been utilised in the 
determination of tryptophan-tyrosine ratios in proteins [160]. The positive feature 
present at 286 nm is followed by a broad negative feature at 270 nm, both of which 
are present in the previously reported spectra of Trp [154,155,156,165]. The reported 
sensitivity of Trp to its local environment was then confirmed by changing the 
solvent used to dissolve the amino acid, as shown in Figure 4-4.   
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Figure 4- 4: MCD spectrum (250 – 350 nm) of Trp, PBS (black line) and Trp 
in 25% ethanol / 75% PBS (green line). 14.8 µg/ml (71 µM), 1 cm path 
length, 1 second integration, 1 mm slit. Note the difference at 286 nm, 
possible due to affecting the vibrational fine detail of the chromophore. 
 
Altering the solvent environment for the amino acid alters the MCD signal of Trp 
(Figure 4-4). This has manifested itself in a slightly broader peak at 292 nm, and a 
more intense positive 286 nm feature.  The broad negative feature at 267 nm remains 
unchanged, suggesting that this may not be where observable changes will occur in 
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future experiments. Interestingly, the intensity of the 292 nm peak remains constant 
in this instance, suggesting that changes which may be observed during ligand 
binding will be to the position of the 292 nm peak, rather than to its intensity, as was 
observed during unfolding experiments reported in the literature [158]. The positive 
feature at 286 nm also appears to be sensitive to changes in the amino acid 
environment, suggesting that this little studied feature could be of interest in later 
experiments. 
 
After confirming that Trp is indeed sensitive to its local environment, several 
proteins were proposed for assessing this approach. One of these involves the use of 
FGF2. This protein was used for its defined interaction with heparin. FGF-2 has a 
single Trp four amino acids apart from the heparin-binding site at the start of a -
strand [129]. It was reported that heparin binding to FGF-2 induces structural 
changes within the protein, however, no direct interaction between this Trp and 
heparin is thought to take place [139,166]. This system should allow for the 
observation of changes to the environment of tryptophan occurring from the 
restructuring of the protein.  
 
The second study utilises SOD1. This protein also has a single Trp residue, and has 
previously been crystallised with several ligands interacting with the tryptophan. One 
of these ligands, 5-fluorouridine, was selected and investigated further here as an 
example, in which a confirmed, direct interaction takes place.  
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Lastly, HEWL was used. Although this protein contains six Trp residues, previous 
work has provided evidence for a direct HS:Trp interaction within the active site by 
its substrate (Chapter 3, [142]), where two Trp residues (W62 and W63) are present 
[143]. This work suggested that, HS and HS in the zinc form (HS(Zn)) have distinct 
interactions with the surface Trp residues within the binding cleft. 
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4.2.2. MCD spectra of FGF2 interactions with heparin. 
 
Figure 4- 5:MCD spectrum (250 – 350 nm) of FGF-2 alone (black line) and 
in the presence of heparin (green line) in PBS, with FGF-2 at 0.7 mg/ml and 
heparin at 3.5 mg/ml. 1 cm path length, 1 mm slit, and 1 second integration 
time were employed. 
 
Initially, the MCD spectrum of FGF-2 was recorded in the presence and absence of 
heparin (Figure 4-5) in conditions that replicate previous work [140,166]. As shown 
in Figure 4-5, despite the known interaction between the ligand and the protein, there 
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were no changes to the spectra. This indicates that there is no direct interaction 
between the Trp in this protein and the ligand as expected, and that changes to either 
the main 292 nm MCD feature, or the 286 nm shoulder will be due to direct changes 
in the local environment of Trp and its interactions and not the result of global 
secondary structural changes as a consequence of binding. It is interesting to note 
that this is the only case in which the shoulder at 286 nm is absent, indicating that the 
local environment of the Trp may have a large influence on the observed A 
component, whether it be from local interactions with the conformation of the 
protein around the amino acid, or through interactions with external factors, buffer or 
ligands. The proposed binding site is 4 amino acids removed from the Trp position in 
the sequence at the start of a segment of -strand. This result suggests that, if there 
are to be any interactions that are observable by MCD, they either need to be direct, 
or closer than 4 amino acids, thereby altering the electronic configuration of the 
delocalised π-π electron cloud present above and below the indole ring of Trp. This 
result also suggests that MCD is not sensitive to the secondary structure changes 
known to occur during this interaction.  
 
The hypothesis that a direct interaction was required for an altered MCD signal was 
then investigated with SOD1, a protein which is known to have a direct Trp:ligand 
interaction. The interaction of the single Trp in SOD-1 with various ligands was 
confirmed in crystallographic studies [167,168] in which it was demonstrated that 
four ligands interacted with the sole Trp residue within the “drug pocket”. This 
interaction was through π-π stacking of the ligands with the amino acid side chain. In 
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this study one of these ligands has been selected and its interactions with SOD-1 
investigated (Figures 4-6 - 4-10).  
 
4.2.3. Confirmation of SOD1 interactions with ligand in solution. 
 
Initially, investigations sought to confirm that the selected ligand, 5-fluorouridine 
interacted with SOD-1 in solution. This was achieved using three methods; far 
UVCD, near UVCD spectroscopy and a thermal degradation of the protein in the 
absence and presence of the ligand, tracked using far UVCD.  
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Figure 4- 6: Figure 4-6A shows the far UVCD (180-260 nm) spectrum of 
SOD-1 alone (black line 0.03 µM) and in the presence of the ligand 5-
flurouridine (blue line, 1:1 Molar ratio). The red line is the ligand alone, 
recorded with 1 second integration time, 0.1 mm path length. B shows the 
near UVCD (270 – 320 nm) of the same samples (SOD-1: 0.16 µM, ligand: 
1:1 molar ratio) in panel A. These spectra were recorded using 1 mm path 
length cell and 3 second integration time. All samples were recorded in 20 
mM phosphate buffer. 
 
Figure 4-6, panel A, shows the far UVCD of SOD-1 in the presence (blue line) and 
absence of the ligand (black line), and also the ligand alone (red line).  The near 
UVCD spectrum is also shown in Figure 4-6B, with matching colour coding. Figure 
4-6A shows first that, when SOD-1 is in the presence of the ligand, there is a 
substantial spectral change around the large negative feature at 205 nm. This is 
manifest in a positive contribution, but one that does not, or very minimally, affect 
the positive feature present at 190 nm. This suggests a possible increase in -turns, 
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known to exhibit a positive feature at 205 nm. The observed spectral change can only 
be attributed to alterations in the protein conformation because there are no chiral 
chromophores in the ligand that are active at these wavelengths as demonstrated by 
the featureless spectrum of the ligand in Figure 4-6A (red line). The near UVCD 
spectrum is dominated under these specific conditions by the signal contribution 
from the ligand, peaking at ~275 nm. There is a change within the protein:ligand 
spectrum in comparison to either the protein or ligand spectra alone, providing 
evidence of an interaction, in agreement with the far UVCD experiment.  
 
 
Figure 4- 7: A SOD-1 unfolding pathway as tracked by far UVCD 
spectroscopy (180-260 nm) in a temperature series from 10 °C (red) to (blue) 
90 °C  in 5°C steps, followed by a final 20 °C step. SOD-1 at 0.03 µM in a 0.1 
mm path length cell and a 1 second integration time. B: A repeat of sample A 
conditions in the presence of the ligand, 5-flourouridine, 1:1 molar ratio. C: 
PCA analysis of data presented in A and B showing the structural changes 
between each temperature step in the experiment.  This experiment shows 
that the unfolding pathways are subtly different in the presence of the ligand 
but, generally, they follow a similar pathway, the differences occurring mostly 
in component 2. 
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Figure 4-7 shows the denaturation profile of SOD-1 as tracked by far UVCD in the 
absence or presence of the ligand. The temperature series employed during this 
experiment was 10°C (red) to (blue) 90 °C (in 5°C steps), and a final step where the 
temperature was returned to 20 °C. The sample was held at each temperature to 
equilibrate before a single scan was recorded (180-260 nm) to track the structure 
within the protein at that temperature. Although a single scan is susceptible to an 
increased noise (twice as much noise compared to 4 scans), this method minimises 
sample damage via the UV degradation method at each point, and can be used to 
reveal the unfolding pathway of the protein when subjected to a temperature 
gradient. This pathway was then analysed using principal component analysis 
(Figure 4-7C) where a direct comparison of the unfolding pathways can be observed. 
Both samples have broadly similar unfolding pathways, however, these do not share 
the same secondary structure – in agreement with the previous experiment (Figure 4-
6A). There is a slight difference between SOD-1 alone (red line) which gains more 
of component 2 as it unfolds and SOD-1 with ligand which does not. However, both 
samples do start and finish at similar points around the dominant contributor, 
component 1. Upon returning to 20°C, both samples exhibit the same refolding 
mechanism. The slightly altered thermal denaturation pathways, coupled with the 
distinct spectral features in a region that reports protein secondary structure, 
alongside that of an alteration in the spectrum from the ligand in the near UV, 
provide evidence of an interaction occurring under these conditions. This provides 
added confidence in the proposed experiment to use this ligand protein combination 
for further MCD studies as an exemplar of a ligand that is known to interact directly 
with a Trp residue. 
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4.2.4. MCD spectra of SOD1 in the presence and absence of ligand. 
 
 
Figure 4- 8: MCD (270-320 nm) spectra of SOD-1 alone (0.15 mM, black 
line) and SOD-1 in the presence of the ligand, 5-flourouridine (1:1 molar 
ratio, blue line, normalised to SOD-1 maximal signal). Samples recorded with 
1 mm path length cell, 3 second integration time. Spectra normalized to 
maximal value of the positive feature at 292 nm. This shows a significant 
(P<0.001, 286 nm) change in the presence of the ligand demonstrating an 
interaction between ligand and protein. Spectra are an average of 4 complete 
cycles of north to south and south to north orientations of magnet.  
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Figure 4- 9: MCD (270-320 nm) spectra of SOD-1 alone (0.15 mM, black 
line) and SOD-1 in the presence of the ligand, 5-flourouridine (1:1 molar 
ratio, blue line, normalised to SOD-1 maximal signal). Ligand alone (green 
line) and ligand + protein, (red line) to demonstrate the additive theoretical 
spectra normalised to maximal SOD-1 signal. Samples recorded with 1 mm 
path length cell, 3 second integration time.  
 
The investigation of SOD-1 with its ligand, 5-flourouridine, demonstrates that an 
MCD spectral change (Figure 4-8) occurs upon introduction of a ligand that is 
known to interact directly with the Trp of SOD-1 (SOD-1: black line, SOD-
1:Ligand: blue line). The ligand alone has a broad positive feature  (Figure 4-9, green 
line). The two main features of these changes are the peak broadening of the positive 
292 nm feature, and the shoulder centred around 284 nm, which is significantly 
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different from that of the SOD-1 alone (P<0.0001, 284 nm). Shown in Figure 4-9 is 
the theoretical spectrum of the ligand in the presence of protein in which no 
interactions are taking place, a purely additive case that has been treated in the same 
way as the observed data. This theoretical spectrum is different to the observed 
Trp:ligand spectrum indicating an interaction between the ligand and the Trp. While 
it can be seen in Figure 4-9 (green line) that the ligand itself has a MCD signal, it is 
featureless, so changes observed at 286 nm are thought to come directly from the Trp 
amino acid residue, consistent with other changes observed within this chapter. 
Studying the data with the benefit of having other data sets and published data it 
becomes apparent that there should not be a negative feature above 310 nm, and the 
features at 275 for Tyr and Trp have negative features, as shown for the dominant 
Trp in Figures 4-2 and 4-3.  In addition to this, the height of the features at 292 nm is 
greater than expected from a Trp at 0.15 mM in a 1.4 T magnet at 1 mm path length.  
 
The possibility of light scattering as a source of this result was investigated, 
however, there is no indication within this data set that this phenomenon has 
occurred. The voltages were comfortably below the upper accepted levels (max 
voltages, <400 mV) and there is no sign of scattering within the data shown in Figure 
4-6B which is a recording of the same sample in the same cell subsequent to the 
MCD measurements in the presence of a dummy magnet. It was further investigated 
whether this could be an induced effect within the buffer system in the presence of a 
magnetic field, and would therefore need to be corrected for. 
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It was decided to treat the ligand spectrum, which appears to be totally featureless, as 
a baseline and subtract it (see Figure 4-10). 
 
 
Figure 4- 10: MCD (270-320 nm) spectra of SOD-1 alone with the green line 
subtracted (0.15 mM, black line) and SOD-1 in the presence of the ligand, 5-
flourouridine with the green line subtracted (1:1 molar ratio, blue line, 
normalised to SOD-1 maximal signal). Ligand alone, (green line) herein used 
as a baseline for the other two spectra. Samples recorded with 1 mm path 
length cell, 3 second integration time.  
 
As can be seen in Figure 4-10, the ligand spectrum has been subtracted the 
experimental spectra and this has given a new set of MCD spectra for the SOD-1 and 
SOD-1:ligand. There are now no features early in the spectra and the broad feature 
between 270 and 280 nm now has a negative sign. After having the ligand subtracted 
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as a background the signal intensity at 292 nm is now at the expected amplitude for a 
Trp at 0.15 mM in a 1 mm path length cell with a 1.4 T magnetic field. The signal 
size of ~2 units in Figure 4-10 equates to ~ 0.1 unit for 1 µM of Trp present (for a 
1cm path length cell), and if compared with Figure 4-3, which has a signal size of 
~6.5 from a 1 cm path length at 71 µM, this also equates to ~0.1 unit per 1 µM of 
Trp in a 1 cm path length cell. These observations combined indicated that Figure 10 
is the true MCD spectrum of SOD-1 and SOD-1:ligand. The fact that the ratios 
between peak heights and features are not altered by subtracting the same spectra 
from both the previous analyses confirms that these spectra demonstrate an 
interaction between the protein and ligand, that is statistically significant at 286 nm. 
 
4.2.5 MCD spectra of HEWL in the presence and absence of GAG ligands 
 
An additional protein, HEWL, has been studied as an example of protein:heparan 
sulfate interactions with Trp. The protein has six Trp, two of which are situated in 
the active site [143], the proposed binding site for HS.  Earlier work discussed in 
chapter 3 and in Hughes et al (2012, [142]) suggests that, although their interactions 
with HEWL result in similar secondary structure changes, (Chapter 3), there are 
differences in how these ligands (HS and HS(Zn)) interact with the protein, see 
Figure 3-2 of Chapter 3. Here the MCD spectra for this protein in the absence and 
presence of the two ligands (HS and HS(zn)) is presented (Figure 4-11), which again 
show changes in the spectrum comparable with the contribution of Trp, and 
consistent with a direct interaction of the HS ligands with the Trp residues at 
positions 62 and 63. 
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Figure 4- 11:  MCD spectra of HEWL 0.4 mg/ml, 12.5 mM NaCl PBS, 1 cm 
path length, 3 second integration time, HS and HS(Zn) at 0.03 mg/ml. 
Spectra of HEWL:HS (red line) and HEWL:HS(Zn) (blue line) have been 
adjusted to equal the maxima value of HEWL alone (black line). Recorded 
using a 1.4 T magnet.  Standard deviations are shown at 286 nm, where 
signals involving both ligands are statistically different from the signal of 
HEWL alone (p 0.0002). 
 
Figure 4-11 shows the spectrum of HEWL, which is consistent with the literature 
spectra [158,160]. The samples used to collect the data in the presence of ligand, in 
both cases had a tendency to aggregate within the cell, causing some scattering noise. 
To deal with this, samples were centrifuged prior to measurement and the 
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supernatant removed for subsequent measurement. This resulted in some loss of 
protein in the pellet. The data have therefore been normalized to the maximum 
amplitude of the HEWL alone sample (Figure 4-11, black line). The result is that 
only the shape and position of features is relevant here, and not the values of the 
feature amplitudes – although relative amplitudes within a spectrum should be 
considered. Figure 4-11 shows that with the addition of HS(zn) (blue line) several 
features change in the spectrum. These are manifested in the red shift of the broad 
negative feature ~267 nm. This feature is a result of both Trp and Tyr amino acids 
(with negative contributions at 267 and 275 nm respectively). There is also an 
increase in the intensity of the shoulder, apparent at 286 nm, and a slight blue shift of 
the main positive peak present. These changes are consistent with the hypothesis that 
a ligand-Trp interaction is causing an alteration in the Trp contribution. It is known 
that the Tyr negative band typically present at 275 nm is able to red shift 
progressively to 292 nm (pH 12.1) above pH 8 due to it becoming ionized. If this 
were the case then that would be expected to have a negative influence on the 
shoulder at 286 nm, leading to a negative contribution, not the positive one that is 
observed here. If it were the case that the Tyr had blue shifted, then we would not 
expect the broad negative feature as a whole to be red shifted. It is also to be 
considered that the relative contributions of these signals, since tyrosine is a 
relatively weak contributor to the near UV MCD signals, and in this protein being at 
a 2:1 ratio lower abundance than Trp, it can be asserted that changes in this spectrum 
are to be assigned to contributions from Trp. The small blue shift observed in the 
positive feature at 292 nm could be attributed to the resulting conformational 
changes, as previously observed. It is of note that previous experiments have shown 
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that at high Tyr to Trp ratios (>35:1) causes the 292 nm feature to red shift by 1 nm, 
indicating again that this shift is not due to the possible alteration of the local 
environment of the environment of Tyr residues. Figure 4-11 also shows that HS (red 
line), induces very similar changes to HS(Zn). These changes include the common 
feature at 286 nm where, again, the change relative to HEWL alone is statistically 
significant (p≤0.0002). 
 
4.3. Discussion of results; MCD is suitable for showing direct Trp:GAG 
interactions 
 
Here it is has been shown that we can observe ligand binding at ~284-286 nm in 
MCD spectra and that this area is susceptible to local environmental changes. Figure 
4-4 demonstrates this susceptibility, the changes observed are probably due to 
hydrogen bonds that are being formed or broken via a direct interaction between the 
Trp and ligand.  MCD has been shown previously to demonstrate protein:ligand 
interactions [164]. The authors observed a decrease in signal amplitude at 292 nm 
and claimed that the simplest explanation would be that this is the result of a ligand-
binding event, and the 292 nm feature has subsequently been used again to monitor 
hydrogen bonding [162]. However, this has not been observed to be the case in the 
work conducted herein, one clear example would be the SOD experiment, where 
there is a proven interaction with the Trp through crystallographic studies and yet no 
positional change in the feature at 292 nm. This lead us to propose a new area of 
interest within a spectrum at 286 nm, so far not explored using this technique, as a 
sensitive region of the spectrum for detection of Trp:ligand interactions. 
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Any further work on this topic would focus on establishing additional proof of what 
was observed here, and the mechanism by which the signal change at 286 nm is 
manifested. Definitive proof of direct Trp:ligand interactions could be provided by 
the heavy labelling of the nitrogen atom (
15
N) in a specific tryptophan residue within 
a protein, such as HEWL, and performing a parallel experiment using NMR to 
observe the direct interaction in solution at the atomic level. The heavy labelling of a 
Trp could prove to be one method of isolating a single Trp in a protein such as 
HEWL which has six Trps, by the 
15
N effecting the electronic configuration of the 
amino acid and therefore altering the signal to provide a means of selecting solely 
that contribution. An alternative method of obtaining further evidence of what has 
been observed here would be to modify exposed Trp residues through indole 
chemistry to add a blocking methyl group to the amino acid, thereby preventing 
binding because of steric hinderence [150].  
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Chapter 5: Investigating the interactions between non-active 
heparin like compounds derived from the shrimp L. Vannamei 
and Antithrombin. 
 
5.1. Introduction. 
 
This chapter will investigate the structural effects of the binding of antithrombin 
(AT) to heparin and the synthetically derived pentassacharide, which is described 
below. The aim of this investigation is to determine the structural differences in the 
interactions of AT with several heparin derivatives of different structures. The 
Pentasaccharide refered to herein is a pharmaceutical drug sometimes known as 
Arixtra or Fondaparinux, Figure 5-1. 
 
Figure 5- 1:  The structure of the chemically synthesised pentasaccharide 
sequence showing the important rare 3-O-sulfate group.  
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5.1.1. Antithrombin. 
 
AT is a serine protease inhibitor synthesised in the liver and discovered in the early 
20
th
 century. It is a 58 kDa protein that contains four glycosylation sites in its major 
form, 432 amino acids and three disulphide bridges. The carbohydrate component 
accounts for 15% of the total mass, and human AT [169] is present at between 14 
and 0.12 mg/ml in serum samples [170,171]. The main targets for the activity of AT 
are thrombin, factor IIa and factor Xa, however, to a lesser extent, it is also known to 
inhibit urokinase, trypsin, plasmin, kallikrein, factors IXa, XIa, XIIa, and tPA 
[172,173,174,175]. AT circulates in the blood with minimal apparent activity until it 
binds with its presumed ligand, HS, on the endothelial blood vessel cell walls. Upon 
activation, AT binds thrombin to form a tightly bound complex that is then removed 
from circulation [176,177]. The addition of heparin to AT can increase its activity 
against thrombin up to 4,000 fold. The activation of AT by full length heparin 
against factor Xa is around 500 fold higher [178]. Factor Xa is a key factor in the 
intrinsic coagulation pathway processing prothrombin into thrombin, a key step in 
blood coagulation. The activity of AT against factor Xa decreases the rate of 
coagulation. 
 
5.1.2. Heparin, and the discovery of the pentasaccharide sequence. 
 
Heparin, first discovered in 1916 [179] for its anticoagulant properties, was 
associated with a heparin co-factor in 1939 [180], which was confirmed to be AT in 
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the 1950’s [181,182]. In the following years attempts were made to relate the activity 
of heparin to its size, degree of sulphation and N-sulfate content [183,184] before the 
discovery of a high affinity fraction in 1976, by separation using analytical 
centrifugation [185]. This result appeared to suggest some specificity within the 
heparin samples for AT, implying a preferential binding to a specific sulphation 
pattern [185]. The fractionation of heparin led to an increase in activity of the active 
fraction from 155 U/mg to 248-388 U/mg (high affinity fraction, HA). The unbound 
heparin (low affinity fraction) on the other hand lost virtually all activity, reducing it 
to 19-52 U/mg. A high affinity fraction was also collected in a separate study using 
affinity chromatography [186]. The resulting work on this fraction to isolate an 
active component took the form of enzymatic degradation prior to affinity 
chromatography, which demonstrated that small fragments of heparin as low as 
hexasaccharides could bind to AT [187]. In the same year an investigation into the 
effect of size on AT anti Xa activity demonstrated that, while thrombin inactivation 
by AT required a large heparin fragment, the inhibition of factor Xa was size 
independent [188]. In 1978, it was observed that the Xa activity of heparin could not 
be attributed solely to the availability of binding sites related to the length alone, 
leading to the suggestion that a specific dodecasaccharide sequence may be 
responsible for activity [189].  Although a specific sequence for Xa activity was 
proposed, the authors warned against the interpretation of a ‘specific 
dodecasaccharide sequence’ as meaning only one possible binding sequence [189]. It 
was also suggested that the low affinity fraction, which maintains some activity, 
sometimes attributed to contamination, may actually be ‘ascribed to sequences that 
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bind less strongly… …and result in partial activation of AT’ [189]. Progress towards 
the discovery of an active sequence in heparin was made by Rosenberg, who 
observed an enrichment of the saccharides D-glucuronic acid and N-acetyl-D-
glucosamine [190,191], proposing that a tetrasaccharide was required for activity. 
This tetrasaccharide was also found in the low affinity fraction however, against the 
supposition that a more defined structure was required. This theory was further 
developed by the proposal of a complete sequence that included the latter 
tetrasaccharide in 1979 [192], later refined to an octasaccharide [193]. 
 
Parallel to these investigations was a drive by the Choay laboratory to find the 
smallest heparin fragment capable of binding to AT and inhibiting the activity of 
factor Xa. They approached the task using both partial nitrous acid fragmentation 
[194] and enzymatic digestion of heparin [195]. These investigations lead to the 
observation of a new signal at 57.7 ppm in 
13
C NMR experiments, exclusively 
present in the active octossacharides [194,196]. Subsequent experiments, to identify 
the missing structural element absent from previous analysis of the active fragment, 
led to the discovery of the important 3-O-sulfate on the 3,6-di-O-sulfated D-
glucosamine residue [38]. Within the octasaccharide unit a small amount of 
hexasaccharide was observed. Investigating further, it was observed that this 
contained the NMR peak previously observed at 58 ppm [197]. This then led, via two 
independent routes, to the proposal of an active pentasacchaide with the same 
affinity as the previously proposed octasaccharide [198,199]. This hypothesis was 
tested via a synthesised pure compound in 1991 [200], and was found to maintain the 
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same high affinity for AT [201]. Two tetrassacharides were also tested, which 
showed significantly lower affinity (2 mM v 50 µM disassociation constant), 
showing that a pentasacchaide was indeed the minimum sequence required to bind to 
AT [202].  
 
Research to this point arrived at the conclusion that a particular heparin sulfation 
sequence was responsible for AT activation and binding. This sequence was marked 
by the rare 3-O-sulfate within the synthesised pentasaccharide and once synthesised 
on a commercial scale, became a successful anticoagulant drug targeting the AT anti-
Xa activity. While this treatment in most cases is highly effective, there are 
occasions in which adverse reactions can occur. It is known, for example, that 
patients who have undergone vasectomies can develop an allergic reaction to the 
antidote of heparin based anticoagulants, protamine sulfate [203]. Importantly, it is 
also difficult to neutralise pentasaccharide with protamine due to its small size, 
which is currently used for this purpose after surgery and has led to bleeding 
complications [204,205,206,207].  
 
5.1.3. Potential therapeutic targets of heparin based drugs. 
 
Alternative heparin based drugs have been developed in the form of low molecular 
weight heparins (LMWH). The main driver towards LMWH, each with a unique 
activity profile, was to avoid heparin-induced thrombocytopenia (HIT) caused by 
antibodies to the aggregates of heparin and platelet factor IV, which in turn can lead 
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to HIT thrombosis, and simultaneously be capable of selectively targeting AT and 
being too small to interact with thrombin or platelet factor IV. Heparin also exhibits 
many alternative activities that are thus far under-exploited [208]. Heparin can have 
activity as an anti-inflammatory agent, cause angiogenesis and also interact with a 
wide range of proteins involved in many disease states [54] including cancer, and is 
actually becoming a target for some cancer therapies [209].  There is hence a need 
for new compounds that both exhibit antithrombotic activity, but without the 
problems of the existing array of heparin based compounds such as the 
pharmaceutical agent pentasaccharide. There is also a demand for drugs that lack this 
activity, but maintain useful activities against other therapeutic targets.  
 
5.1.4. Shrimp heparinoids: An apparent enigma. 
 
Shrimp heparinoids (SH) purified from the viscera of the Atlantic shrimp 
Litopenaeus vannamei contained the distinctive 3-O-sulfate thought to be the marker 
for AT activity [210], yet these lacked the increased AT activity expected [109]. 
However, they do exhibit interesting properties that suggest they could be used as a 
basis for novel drug candidates targeting a range of desirable activities, including 
anti-angiogenic effects, and anti-inflammatory effects whilst maintaining the 
desirable negligible haemorrhagic activities [109,210]. Despite its lack of AT 
activity the SH compounds were eluted in the same fraction as the classic high 
affinity heparin fraction at 0.75-1.5 M NaCl. This result led to the current 
investigation to determine the characteristics of active and inactive AT interactions 
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with the polysacchairdes SH1 and SH2, unfractionated heparin (UFH), and the 
classic pentasaccharide sequence. It was hypothesised that the resulting secondary 
structures would be distinct between active and non-active heparin structures.  
 
In line with our initial hypothesis that the interaction of active and inactive sugars 
with AT would result in AT adopting distinct secondary structures, experiments were 
designed to investigate this. The results of this investigation are presented below. 
Initially, SRCD of AT complexed with the various sugars that induce a range of anti 
Xa activities in AT were investigated (Figure 5-1). The sugars used in this study are 
the synthetic pharmaceutical Pentasaccharide, UFH and SH1 and 2. SH1 and 2 are 
sugars derived from shrimps, and are composed of the heparin disaccharide repeat 
with the only difference being the size of the molecule in comparison to UFH. They 
also contain the 3O sulfate described as been responsible for AT anti Xa activity.  
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5.2. Results. 
 
5.2.1. SRCD spectra and analysis. 
 
5.2.1.1. The effects of inactive heparin containing 3-O-sulfation on the structure 
of AT. Comparison to UFH and highly active synthetic pentasaccharide.  
 
 
Figure 5- 2: A: SRCD spectra (185 – 260 nm) of native AT (0.4 mg/ml 12.5 
mM NaCl PBS buffer, 0.1 mm path length, 0.5 mm slit and average of 4 
scans). B: SRCD spectra of AT with various GAG derivatives (0.8 mg/ml), 
under the same conditions as A.  
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Table 5- 1: Secondary structural analysis of the spectra provided in Figure 5-
2. Analysis conducted using the CDNN software, with complex base set 
reference proteins (version 2.1 [98]). 
Sample AT AT:pentasaccharide AT:UFH AT:SH1 AT:SH2 
Helix 80.70% 85.90% 85.80% 80.90% 87.30% 
Antiparallel 0.10% 0.10% 0.10% 0.10% 0.10% 
Parallel 2.20% 1.80% 1.70% 2.10% 1.50% 
Beta-Turn 9.80% 8.70% 9.10% 9.90% 8.80% 
Random. Coil 8.00% 6.30% 5.30% 7.30% 4.80% 
Total Sum 100.80% 102.80% 102.00% 100.30% 102.5% 
 
 
The complexes were further investigated via UV degradation over the course of 35 
scans, and their secondary structures were tracked to determine how the degradation 
pathways differed when complexed with the various GAGs, as a means of 
differentiating otherwise quite similar CD spectra. 
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5.2.1.2. Comparing and differentiating AT:GAG complexes. 
 
Figure 5- 3: SRCD spectra (185 – 260 nm) of native AT over a 35 scan 
degradation (0.4 mg/ml 12.5 mM NaCl PBS buffer, 0.1 mm path length, 0.5 
mm slit. Every 3rd scan is shown, red to blue) alone and with various GAG 
oligosaccharides (0.8 mg/ml). The panels represent the following samples A, 
AT; B, AT:pentasaccharide; C, AT:SH1; D, AT:SH2 and E, AT:UFH. 
To allow for a direct comparison between the unfolding pathways the data from 
Figure 5-3 above were analysed using PCA. The initial data analysis showed that the 
first three components accounted for the major contributions to the observed 
variation in the samples (22.5%, 12.3% and 9.4% respectively, 44.2% cumulatively) 
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Figure 5- 4: A Top left is the scree plot for the amount of variance accounted 
for by each component to explaining the variance from all of the spectra 
shown in Figure 5-2. Top Right, component 1, bottom left, component 2, 
bottom right, component 3. The components 1, 2 and 3 explain 22.5%, 
12.3% and 9.4% of the overall variance observed in the raw data in Figure 5-
3 respectively. 
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Figure 5- 5: PCA of AT with various GAG oligosaccharides showing the degradation process over the course of 35 scans (blue to 
red) in the far UV (180-260 nm). A: shows component 1 v component 2, B: is component 1 v 3 and C: is component 2 v 3. The 
components 1, 2 and 3 explain 22.5%, 12.3% and 9.4% of the overall variance observed in the raw data in Figure 5-3. 
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5.2.2. DSF and activity (against factor Xa) results. 
 
5.2.2.1. Stabilisation, not conformation, determines activity. 
 
 
Figure 5- 6: Relationship between anticoagulant activity (anti-factor Xa) and 
the melting temperature (Tm, °C) of native AT in the presence of 17 
polysaccharide derivatives (5 plant and 12 GAG saccharides). Activity values 
are either measured in the laboratory (by collaborators, triangles) or by using 
manufacturers values (circle). The dashed line is a line of best fit, with six 
values coinciding at (0,0) excluding the pentasaccharide in the upper right 
corner due to it being the only pure, non-heterogeneous, compound. 
Reproduced from [141].   
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Table 5- 2: The stability (°C) of AT alone and in the presence of various 
polysaccharide ligands as measured by DSF. Also listed is the anti Xa 
activity of these AT:ligand complexes measured experimentally. 
Sample Melting Temperature (°C) Anti-Xa Activity (IU/mg) 
AT 49.5 (±2.0) - 
AT:Pentasaccharide 61.9 (±0.8) 700 
AT:UFH 57.1 (±0.5) 190 
AT:SH1 54.5 (±1.1) ≤10 
AT:SH2 53.8 (±1.0) ≤10 
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5.3. Discussion. 
 
5.3.1. Justification for using freshly purified human AT. 
 
AT was purified fresh from plasma using a salt gradient eluting from heparin affinity 
beads. This technique was used because native AT from plasma was required, 
allowing the protein to be kept in solution and at constant pH throughout all 
experiments. The treatment of AT purchased from commercial sources involves 
pasteurisation and lyophilisation. This has been shown to result in a protein that, 
while maintaining activity, possesses different secondary structure and also altered 
thermal stability measured using DSF [83,84] (data not shown and conducted by Ms 
N. Veraldi, Ronzoni Institute, Milan). The native AT purified from human plasma 
also maintained all complex glycosylation, including the rarer glycosylated form 
where the glycosylation site, Asn 135, which arises in 5-10% of cases [211,212]. The 
SRCD experiments were conducted in 12.5 mM PBS, so allowing the experimental 
conditions to approach the biological state without compromising the high quality 
structural data by excessive UV absorption caused by chloride ions (salt 
concentrations about 10 x less than physiological [213], and AT at 0.4 mg/ml; 3 x 
lower than the physiological levels [214]).  
 
5.3.2. Discussion of SRCD experiments: Structural similarities induced in AT 
between active and non-active compounds. 
 
The initial experiment, recording the SRCD spectrum of AT alone in solution agrees 
with previous work that states AT consists mainly of -helical protein with some -
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sheet (Figure 5-2A, Table 5-1). When the spectrum was recorded in the presence of 
pentasaccharide (Figure 5-2B, blue line) there was an expected change in the 
increase of alpha helix as the reported reactive centre loop is expelled and converted 
from -sheet to -helix [215] (Table 5-1). It has been observed that this change 
resulted in a 5.2% increase in -helical content, at the expense of random coil, 
parallel -sheet and -turns (Table 5-1). The average structural changes induced in 
AT by UFH were similar which, being an active compound, was expected. The 
inactive compound shrimp heparin 1 (SH1, Figure 5-2B, brown line) showed some 
evidence of interaction with AT, resulting in a small conformational change, slightly 
increasing in -helical content (Table 5-1). The SRCD evidence confirms the 
interaction as SRCD is known to be extremely sensitive to detecting small changes in 
protein structure [90]. It must be considered that the purification process of the SH 
compounds included an AT affinity step, indicating that, despite the small 
conformational changes observed in SRCD these compounds have been purified on 
the basis of interactions with AT. Further evidence of the interaction was provided in 
the form of DSF measurements showing a subtle stabilisation of AT (from 49.5°C 
±2.0, to 53.8 °C ±1.0). The observation presented below, however, led to the 
previous hypothesis, that these inactive shrimp heparins would induce distinct 
secondary structures, being rejected and a new explanation of the significance of 
structural changes induced in AT by heparin derivatives being sought. 
 
The compound labelled SH2 induced remarkably similar secondary structural 
changes on average to that of pentassacharide and UFH. This compound resulted in a 
6.6% rise in -helical content, compared to 5.2% with pentasaccharide. However, 
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since the measured anticoagulant activity of SH2 is below 10 IU/mg of activity, this 
result was unexpected.  
 
5.3.3. Differentiation of similar complexes by UV degradation. 
 
It was then decided that an alternative method was required to differentiate these 
complexes so a UV degradation experiment was conducted in order to track their 
unfolding kinetics, the results of which are shown in Figure 5-3. These results do 
show some differences between the complexes, especially around the positive feature 
at 190-200 nm and the 220 nm negative feature. These data were collated into a 
single matrix and PCA was performed on the spectra to allow a direct comparison of 
the changes that occur during the perturbation. These changes are explained in terms 
of independent components that together account for 100% of the variance observed 
from the mean “spectrum” of all the spectra input into the matrix (created via the 
mean centring of the data). These components are weighted in terms of how much 
variance each explains and can be used to follow directly the process occurring 
during a stepwise structural change such as this. This example of PCA first indicates 
that there are many complex processes occurring simultaneously, evinced by the low 
weighting apportioned to even the first component, 22.5% v 56 and 54.5 % observed 
for component 1 in Chapter 3 [142]. There are 3 major components within this data 
set, shown in the scree plot (Figure 5-4A). These are shown in panels Figure 5-4B, C 
and D for components 1, 2 and 3 respectively. They are weighted as explaining 22.5, 
12.3, and 9.4% of the total variance, collectively covering 44.2% of the total variance 
observed in the raw data in Figure 5-3. A structural assessment of what each 
component represents cannot be attempted. This is largely caused by the fact that 
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during this analysis, if a certain structure were lost from the protein in solution then 
the resulting component would be the inverse of the typical spectral shape of that 
structure. These details would be missed by conventional structural analysis. This 
assumption would also render conventional structural analysis of the raw data from 
Figure 5-3 at different time points inaccurate, because the state of the protein is not 
known at each point, regarding protein length especially since high energy UV 
irradiation could break the protein backbone, so the input parameters regarding 
protein size and therefore molar concentration would be inaccurate. 
 
Therefore, a more qualitative, rather than quantitative approach was taken to 
understanding the changes occurring within the spectra. Using this approach it can be 
stated that within component one (Figure 5-4), the major positive feature present at 
~195 nm, which is in line with the addition of -sheet as stated by Table 1-3, Chapter 
1 (which states -sheet has a positive sign focused at 195 nm) and the positive 
feature around 215 nm could be representative of an increase in -turns. The second 
component is dominated by a classical -helix structure, with a positive feature at 
~195 nm being lower than that expected of an entirely helical spectrum suggesting a 
negative influence around this point. This again could be from increased levels of -
turn, or possible unordered structure. The third component is rather more complex, 
possibly comprising either a mixture of different defined structures, or some new 
undefined structure induced the high intensity UV. There are many different 
structures, defined broadly as “unordered”, that have distinct CD profiles (see Figure 
5-4 of the review by Wallace and Janes 2010 [90]).  These qualitative assessments 
must be taken as best estimate interpretations given the available data thus far, and it 
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must be remembered (evinced by the low weighting of components) that this process 
is a complex one. 
 
The PCA analysis shows that, broadly, all five complexes undergo similar unfolding 
processes demonstrated in Figure 5-5A with comparable increases of both 
component 1 and 2 during the denaturation process. This indicated the addition of 
alpha helix and a reduction of unordered structure. The major difference between the 
samples when taking these two components into consideration is the extents to which 
they denature during the 35 scans. It can be said that AT unfolds in an independent 
manner to the AT:polysacchaide complexes, shown by its initial period of resistance 
to UV stress. The complexes, in contrast, undergo a continuous step-wise unfolding 
with no initial resistance. This panel (Figure 5-5A), representing 34.8% of the total 
variance, again suggests that the interactions between these complexes are in fact 
very similar. When observing the more subtle changes that are accounted for by the 
(difficult to define in secondary structural terms) component 3 (Figures 5-5B and 5-
5C), differences in the unfolding begin to become apparent. It is observable again, 
that AT alone undergoes a different unfolding process to that of AT complexed with 
GAGs. This is demonstrated by the lack of any change in either of the major 
components 1 and 2 during the early stages of the process, but does reveal that some 
more subtle changes are occurring early in the process accounted for by component 
3. This then stops being a contributing factor roughly half way through the process 
employed here, suggesting a two stage unfolding event for AT alone when subjected 
to UV irradiation. Component 3 generally has only a minor influence on the 
unfolding process of AT when complexed, but, by the selective removal of 
component 1 and 2, it is possible to observe each complex individually showing that, 
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despite being similar, they are distinct. This is except for AT:pentasaccharide and 
AT:SH2, which have some major overlaps in their common structures and their 
unfolding pathways for all combinations of components 1, 2 and 3. Their only 
difference is the extent to which each component is changed in each case, not the 
direction or positions within each combination of components. The result is that 
these complexes share similar structural interactions, especially AT:Pentasacchaide 
and AT:SH2. This is contrary to the original hypothesis considering the large 
differences of activity induced in AT against factor Xa. The data, suggesting 
differential stabilities as measured by the intense denaturation process by far UV 
irradiation, were investigated further. To do this, initially, these complexes were 
investigated using DSF and a thermal denaturing technique. It was observed that the 
activity of these compounds were closely linked to the thermal stability induced in 
AT when complexed together (Table 5-2). This trend was then further investigated 
with a collection of GAGs and plant polysaccharides, both sulfated and non-sulfated. 
This collection of polysaccharides were selected to investigate the independence of 
the stability from a particular sequence, or structure in the determination of activity. 
They were used to demonstrate that AT activity does not require a particular GAG 
sequence, or even a GAG. The data were taken from reference [141], but these 
compounds will not be discussed within this thesis. The thermal stability data were 
then plotted against either their reported (by manufacturer), or measured, anti factor 
Xa activity (Figure 5-6, Table 5-2). The data presented provide strong support of the 
revised hypothesis; namely, that the ability of a ligand to stabilise AT when 
complexed determines the level of activity and not the induced secondary structure 
changes. 
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The analysis also raises some important questions regarding the mechanism by 
which pentasaccharide interacts with AT. This product has until now been described 
as a synthetic mimic of a natural fraction of heparin that binds selectively to AT and 
causes this conformational change in the same manner as the natural ligand. This will 
form part of the investigation for Chapter 6, looking at the degradation data in more 
detail through generalised 2D spectroscopy. 
 
5.3.4. AT activity is directly related to complex stability and not solely to a 
sulfation sequence. 
 
These results suggest many questions regarding the core assumptions that have been 
made around the basic mechanism behind AT activation. The results presented here 
do not disagree with the structural work done previously regarding the expulsion of 
the reactive loop when bound to active heparin fragments, however, they do call into 
question the assertion that the 3-O-sulfate is the marker for activity and indeed that 
the induced secondary structural changes are the underlying factor behind AT 
activation. The sarccharides derived from shrimp used in this work contain the 3-O-
sulfate group and, and with the exception of the size of the molecule, are very similar 
to heparin in composition and basic structure sharing an identical dicaccharide repeat 
unit and linkages. Beyond a minimal level size, as noted in the literature [188], the 
chain length is not a factor in anti Xa activity with AT, unlike with thrombin activity, 
so these shrimp heparinoids can be thought of as ‘standard’ heparin molecules, such 
as the UFH used here, which is usually derived from mammalian sauces [210,216].  
These heparinoids have shown during purification to have high affinity for AT, 
eluting in the same fraction as HA heparin. These collective results open up new 
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avenues for anticoagulant drug design, including routes for small molecule activation 
of AT, should a molecule be found that can stabilise AT in a similar manner to the 
results reported here. The results also lend themselves to DSF being used as a 
medium to high throughput assay with which to screen potential ligands for AT 
activity before the more time consuming and costly anti Xa activity assays take 
place. It also raises the question of the mechanism by which the presumed natural 
ligand HS activates this enzyme in the blood and a perhaps more important question 
regarding our understanding of the mechanism of action of the current drugs. It is 
possible that there are many more factors that influence the activity and the resulting 
clinical response than those considered so far, especially as our understanding of its 
natural source material is still being expanded. This is not to say that the current 
drugs available in the form of the synthesised pentasaccharide or range of LMWHs 
are bad or ineffective per se, rather that it demonstrates a lack of real understanding 
regarding their mechanism when admistered to patients, which is an important point 
to realise and if possible address. Doing so would be of vital importance in 
improving these drugs and in the development of novel compounds in which it might 
be desirable to altogether avoid these activities. The idea of heparin being a 
redundant system, and therefore lacking obvious structure (sulfation sequence) to 
activity relationship, is not a novel one. It has been observed for instance in FGFs 
that the stabilisation of the protein is required for its activity, with no clear 
correlation with sulfation patterns within the molecules [46,50,139].  
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5.3.5. Future work, the creation of active compounds from non-active heparin 
fractions. 
 
This new AT hypothesis, that the stabilisation directly correlates with its activity, can 
be tested via covalent cross linking of inactive, or partially active, heparins with the 
protein. This should induce the required stability and a preliminary experiment was 
carried out using EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) a zero-size 
crosslinking agent, and crosslinking protocols previously optimised. The crosslinking 
of UFH and non-affinity (NA) to AT, and the gel filtration purified crosslinked 
product were measured by DSF. The result indicated a change of the AT:UFH 
complex from its original stability to a stability close to that of pentasacchaide (See 
Figure 5-7), its activity has yet to be assessed.  
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Figure 5-7: Preliminary 1st derivative curves from DSF results from the 
covalent crosslinking of inactive (NA, red line left panel) and partially active 
(UFH, red line, right panel) heparin compounds to AT showing a comparable 
stabilisation to that of the active, non-crosslinked, pentasaccharide (Arixtra, 
blue lines). Y-axis represents arbitrary values from 1st derivative 
measurement and X-axis represents temperature in °C.  
 
Alongside these EDC crosslinking experiments several others could be proposed to 
test these hypotheses, including selectively labelling AT in the heparin binding site 
and probing with NMR to discover whether these compounds bind in the same site or 
have various binding sites and modes across the protein. The crosslinking data 
provide a novel route for drug design should these compounds prove to be effective 
in activating AT against factor Xa for instance, heparin is open to chemical 
modification, for example through the addition of thiol groups, which are very 
reactive, opening up many potential additional groups that may be added. This could 
be used to localise the heparin molecule and provide to localised anticoagulant 
activity. 
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Considering the direction the field has taken since the original discovery of the 
pentasacchaide that led to the hypothesised structure (sulfation pattern) function 
relationship, then these results add to a growing body of evidence [36,45,46,139] that 
suggests this is incorrect. In the proceeding ~30 years much effort has been expended 
trying to find more examples of these relationships to no avail. It is therefore 
becoming apparent that an alteration of mind set may be required to advance the 
field, and a shift away from the template driven genetics style to one of a more 
redundant and flexible system that is capable of affecting any responses to a change 
in physiological needs via subtle alterations to the GAGs.  
 
5.4. Author contributions. 
 
This chapter has been a large collaborative project between A Hughes at Liverpool 
University/Diamond Light Source and Dr M Lima of UNIFESP, São Paulo, Brazil. 
As such contributions are listed below; 
 
AT collection from Human plasma: Dr M Lima. 
SRCD experimental design: A Hughes 
SRCD experimental data collection: A Hughes / Dr M Lima 
SRCD analysis: A Hughes 
DSF experimental planning, data analysis and collection: A Hughes (Excepting 
Figure 5-6) 
EDC crosslinking optimisation: A Hughes / Dr M Lima 
AT:GAG cross linking for Figure 5-6: Dr M Lima. 
Chapter concept and direction: A Hughes / Dr M Lima. 
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Chapter 6: An investigation into the application of covariance 
matrix data analysis during a perturbation. 
 
6.1. Introduction. 
 
6.1.1. Covariance matrices and the basic method. 
 
This chapter will aim to investigate the suitability of applying covariance matrices as 
a data analysis tool for increasing the resolution and information available in a 
technique that is low resoution in nature. It will focus initially on the 35 scan AT UV 
degradation shown in Chapter 5, and then will be selectively applied to the 60 scan 
degradation of HEWL investigated in Chapter 3. 
 
Tracking a perturbation, such as a UV degradation, via 2D correlation of the data 
matrix can be a useful method for distinguishing complexes with similar CD spectra, 
in that they may degrade by distinct routes, giving rise to different CD spectra. Two 
examples of this type of perturbation will now be analysed using a number of 
variations of the methods first suggested by Noda [217]. This process of matrix 
manipulation can be employed to probe both synchronous and asynchronous 
correlations within a data set, and was first developed by Noda et al. These two types 
of covariance matrix in their simplest form can give the user different information, 
and these will be described below. 
 
The synchronous covariance matrix reveals those wavelengths that change in phase 
with the perturbation, while the asynchronous covariance matrix selects those that 
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change out of phase during the perturbation. This means that the synchronous 
covariance matrix highlights correlations that are happening simultaneously (in 
phase) with the progression of the perturbation being studied such as temperature, 
concentration or time series for example. In this case the perturbation is the scan 
number – the amount of UV exposure. The Asynchronous covariance matrix 
highlights those changes that occur sequentially to one another, but not 
coincidentally. 
 
The covariance matrix, for both synchronous and asynchronous correlations, is 
derived from the multiplication of a mean centered matrix [2] by the transpose of that 
matrix (Equation 6.1 and 6.2 below, 6.1 – for synchronous covariance and 6.2 for 
asynchronous, HN – Hilbert-Noda matrix), thus multiplying every cell within the 
matrix by every other one and thereby creating a covariance matrix.  
 
6.1: M*M
T 
 
6.2: M*HN*M
T 
 
The Hilbert-Noda transformation matrix is designed to move changes out of phase 
with one another, and does so by multiplying M by a number (derived from the term 
6.3 below) before its multiplication with M
T
. This also assigns all diagonal peaks as 
‘0’ explaining the reason why these matrices feature no diagonal peaks. The details 
of these are explain in detail in Noda and Ozaki’s book [217] 
 
6.3: (1/π(k – j)) 
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In term 6.3 the values on the Hilbert-Noda transformation matrix are calculated. In 
this equation k refers to the column number and j the row number. 
 
The resulting covariance matrices (from either Equation 1 or 2) are then plotted by X 
Y and Z (as colour to represent the degree of correlation). Initially, this approach will 
be used and discussed. Alternative methods will then be explored as possible routes 
to improving resolution, and allowing a more direct comparison between two 
perturbations.  The more standard method introduced above covers Figures 6.1-6.4 
and is described as method 1 in Table 6-1, while later figures refer to alternative 
methods, of which there are four, described below.  
 
6.1.2. Alternative covariance matrices. 
 
The alternative methods developed for this thesis consist of four approaches. First an 
attempt was made to observe how each covariance matrix differs from other 
covariance matrix. This was achieved through the deduction of one covariance 
matrix from the covariance matrix to be compared to. Thereby revealing the 
differences between the two perturbations. This is method 2 in table 6-1. 
 
 The third approach, attempts to correlate two perturbations together using an 
alternative mean centering (MC). This method has an initial MC step across the two 
perturbations (A + B) before perturbations A and B are then correlated independently 
of each other. This method of handling the data removes the features in common 
between A and B, and should highlight features that differ from each other. The 
usual MC method for correlations is for the MC to be through the single perturbation 
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being studied. For an example of the alternative method proposed, if comparing AT 
to AT:pentasaccharide, the usual process would be to mean centre the AT spectrum 
and separately mean centre the AT:pentasaccharide spectrum, but in this situation a 
single mean centre is created across both perturbations, which is then deducted from 
each and then the two correlation matrices are created, as summarised below; 
 
 Matrix A 
 Matrix B 
 A is combined with B to give the matrix AB 
 This is then mean centered AB(MC:AB) 
 This is then separated into each component again as the A and B dimensions 
are unchanged: A(MC:AB), B(MC:AB) 
 Then each matrix (A / B) is correlated in the usual fashion presented in 
Equations 6.1 and 6.2 
 
The fourth method is similar to the first, however, in this case, one of matrices is 
prenormalised to the maximum amplitude of the other matrix, thus eliminating 
amplitude as a contributing factor to the resulting comparison. This method of 
comparison will lose information regarding the extent to which changes happen at a 
particular wavelength, but will provide a better representation of the wavelengths at 
which the correlations differ in each given situation. 
 
A final (fifth) analysis is conducted across all AT degradation spectra in the same 
manner as method one. In this instance only the wavelengths 185-250 nm are 
considered. This is to investigate whether having equal variance at each position 
The application of covariance matrix data analysis during a perturbation. 
 122 
across the spectrum affects the final result. The increased variance at 260 nm is 
discussed in Chapter 7. 
 
As this is a demonstration of an analysis technique and not a full analysis of the data 
at hand, examples from each method of analysis will be analysed for AT 
perturbations and from the methods giving the best results in the AT example will be 
applied to the HEWL perturbations. Methods are summarised in Table 6-1. 
 
Table 6- 1: Summary of the methods utilised with results section. 
Method number Description 
1 Basic covariance matrix of perturbation 
MC across single perturbation 
2 Deduction of two covariance matricies 
created using method 1 from one another 
3 Alternative MC technique. Individual 
covariance matrices are created from 
data sets mean centered across two 
perturbations to be compared. 
4 As method 2, except the covariance 
matrices are normalised prior to 
deduction from one another. 
5 A repeat of method 1, but excluding 
contributions above 245 nm from the 
creation of the covariance matrix. 
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6.2. Results. 
 
6.2.1. AT perturbation analysed by method 1. 
 
Figure 6- 1: A summary of the synchronous covariance matrices of the 35 
scan perturbation of AT alone (A) and in the presence of the ligands 
pentasaccharide (B), SH1 (C), SH2(D), and UFH (E).  As shown in Figure 5-
2. 
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Figure 6- 2: The diagonals of the synchronous covariance plots shown in 
Figure 6-1. This demonstrates variance within the dataset for each complex. 
AT alone (A) and in the presence of the ligands pentasaccharide (B), SH1 
(C), SH2(D), and UFH (E).  
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Figure 6- 3: Synchronous covariance matrix plot of AT in the presence of 
pentasaccharide undergoing a 35 scan UV degradation perturbation 
represented in Chapter 5 Figure 5-2B. This is a more detailed expansion of 
Figure 6-1B. 
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Figure 6- 4: Synchronous covariance matrix plot of AT in the presence of 
SH1 undergoing the 35 scan UV degradation perturbation represented in 
Chapter 5 Figure 5-2C. This is a more detailed expansion of Figure 6-1C. 
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6.2.2. Method 2. Deduction of one AT covariance matrix from another. 
 
 
Figure 6- 5 AT:pentasaccharide covariance matrix (Figure 6-3) minus 
AT:SH1 (Figure 6-4) covariance matrix, revealing differences in correlated 
areas during 35 scan UV degradation experiment. 
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Figure 6-6: AT:pentasaccharide correlation matrix (Figure 6-3) minus 
AT:UFH covariance matrix (not presented), revealing differences in 
correlated areas during the 35 scan UV degradation. 
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6.2.3. Method 3. Mean centring across two AT perturbations to be compared. 
 
Figure 6- 7 AT:pentasaccharide synchronous covariance matrix when mean 
centered in combination with the AT:SH1 perturbation. Perturbations are over 
35 scans of UV degradation. 
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Figure 6- 8: AT:pentasaccharide  asynchronous covariance matrix when 
mean centered in combination with the AT:SH1 perturbation. Perturbations 
over a 35 UV degradation experiment 
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6.2.4. Method 4. Comparison of the differences in two AT covariance matricies 
deducted from one another after prenomalisation. 
 
 
Figure 6- 9: Synchronous covariance matrix of AT:pentasacharide 
(prenormalised to the maximal signal from AH:SH2) with AT:SH2 deducted. 
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Figure 6- 10: Synchronous covariance matrix of AT:SH2 minus AT:SH1 
covariance matrix (prenormalised to the maximal signal from AH:SH2). 
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6.2.5. Method 5. Checking for any artefacts stemming from added noise at 260 
nm. 
 
Figure 6- 11: A summary of the synchronous correlations of the 35 scan 
perturbation of AT alone (A) and in the presence of the ligands 
pentasaccharide (B), SH1 (C), SH2 (D), and UFH (E). These correlations 
only account for the spectrum up to 250 nm. 
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6.2.6. HEWL subjected to method 4, the direct comparison of two covariance 
matricies after prenormalisation. 
 
Figure 6-12: Covariance matrix of HEWL minus covariance matrix of 
HEWL:HS(Zn) following pre-normalisation. The perturbation being followed is 
a 60 scan UV degradation shown in Chapter 3, Figure 3-5. 
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6.2.7. HEWL subjected to method 3, MC across two perturbations to be 
compared. 
 
Figure 6- 13: Synchronous covariance matrix of HEWL undergoing a 60 
scan UV degradation, mean centered with a 60 scan UV degradation of 
HEWL:HS, raw data from Chapter 3 Figure 3-5. 
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Figure 6- 14: Asynchronous covariance matrix of HEWL undergoing a 60 
scan UV degradation mean centered with a 60 scan UV degradation of 
HEWL:HS, raw data from Chapter 3 Figure 3-5. 
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Figure 6- 15: Synchronous covariance of HEWL:HS undergoing a 60 scan 
UV degradation mean centered with a 60 scan UV degradation of HEWL, 
raw data from Chapter 3 Figure 3-5. 
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Figure 6- 16: Asynchronous covariance matrix of HEWL:HS undergoing a 60 
scan UV degradation mean centered with a 60 scan UV degradation of 
HEWL, raw data from Chapter 3 Figure 3-5. 
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Figure 6- 17: Synchronous covariance matrix of HEWL:HS undergoing a 60 
scan UV degradation mean centered with a 60 scan UV degradation of 
HEWL:HS(zn), raw data from Chapter 3 Figure 3-5. 
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Figure 6- 18: Asynchronous covariance matrix of HEWL:HS undergoing a 60 
scan UV degradation mean centered with a 60 scan UV degradation of 
HEWL:HS(zn), raw data from Chapter 3 Figure 3-5. 
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Figure 6- 19: Synchronous covariance matrix of HEWL:HS(Zn) undergoing a 
60 scan UV degradation mean centered with a 60 scan degradation of 
HEWL:HS, raw data from Chapter 3 Figure 3-5. 
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Figure 6- 20: Asynchronous covariance matrix of HEWL:HS(Zn) undergoing 
a 60 scan UV degradation mean centered with a 60 scan UV degradation of 
HEWL:HS, raw data from Chapter 3 Figure 3-5. 
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6.3. Discussion of results. 
 
6.3.1. General covariance matrix interpretation rules and method 1, basic 
covariance matricies applied to AT perturbations. 
 
The synchronous matrix summarized in Figure 6-1, from the first (standard) analysis 
method, highlights wavelengths that change in phase with one another. The peaks on 
the diagonal of these plots (Figure 6-2) reveal their auto-correlations, showing the 
spectral positions at which most change occurs within a spectrum and are always 
positive. The cross-peaks (off the diagonal, Figure 6-1) show which wavelengths are 
correlated together in the covariance matrix. These can be either positive or negative 
providing information on the direction of the change. For example, positive cross-
peaks will indicate that both wavelengths change in the same direction; either 
positively or negatively, while a negative cross peak indicates that the two correlated 
wavelengths change in opposite directions; one in a positive fashion and the other in 
a negative direction.  
 
The asynchronous covariance matrices are more relevant to the third analysis 
technique (alternative MC method). It reveals those wavelengths that change out of 
phase with the perturbation. More interestingly, this correlation can reveal the 
sequential order of events happening via their negative or positive sign (see summary 
in Figure 6-21).  The rule followed, as shown by Noda ([217] Chapter 2.3.2), is that 
if the sign of the cross-peak is positive, then the first variable happens before that of 
the second, and the reverse is true if the sign is negative. This rule is reversed, 
however, if there is a corresponding peak in the synchronous matrix that has a 
The application of covariance matrix data analysis during a perturbation. 
 144 
negative sign (See Figure 6-21). The convention is to observe the upper left half of a 
covariance matrix, above the diagonal. In the example below the asynchronous 
correlation has two positive features in the upper left while the lower right contains 
the negative features.  The rule set out above are for spectra in their simplest cases, 
where the amplitude of individual peaks change without overlap or position shifting, 
to be discussed later. 
 
 
Figure 6- 21: A schematic diagram of the rule used to determine the order of 
events when analysing covariance matrices. The order of events is 
determined by the sign of the cross peaks in the asynchronous correlation 
relative to the sign in the upper left triangle synchronous correlation. If this is 
positive as per A and B, then A happens before B if there is a positive feature 
(or no feature) in the synchronous spectrum. This rule, however, is reversed 
if there is a negative feature present in the synchronous covariance matrix, 
as in the case of C and D. 
 
The auto peaks on the diagonals shown in Figure 6-2 reveal that AT is different to 
AT in all of the complexes, and comparing the synchronous data shown in Figure 6-1 
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it is immediately apparent that there are differences between the complexes during 
the unfolding pathway caused by UV degradation. It is also noteworthy that, contrary 
to how the spectra appear in the raw data (Chapter 5, Figure 5-2), there is no 
evidence in these correlations (Figure 6-1) of any more complex features, such as 
line broadening (two overlapping peaks that change in opposing directions), band 
shifting, or band shifting coupled with intensity changes (for reference [217] Chapter 
4.3). This leads to the conclusion that all of the features observed with the AT dataset 
are arising from independent events on static features. This observation could be 
significant in respect to algorithms for secondary structure, suggesting that they can 
be used for analysis of these types of data. There appears to be an artifact present in 
all correlations at 260 nm, probably due to the initial noise (discussed in Chapter 7) 
but does not appear to contribute to any cross peaks so has been ignored (for 
conformation see section 6.3.5.), rather, the analysis has picked up on this 
wavelength as an area of variation. 
 
The diagonal of the AT correlation (Figure 6-2A) separates it from the other 
correlations by being devoid of correlations, beyond a feature at 190 nm. This single 
feature is relatively intense in comparison to all other correlations, with the exception 
of SH2 (Figure 6-2D), and it is also broad so could contain several contributions 
around that spectral area. The AT:pentasaccharide  (Figure 6-2B) complex shows 
that there are several more points of change with a major correlated change at 196 
nm and then three minor features at 208, 214 and 221 nm that are unique to this 
complex. AT:SH1  (Figure 6-2C) has changes at 192, 196, 220 and 231 nm. The 
double feature around the 195 nm region is unique to this complex and contributes to 
several unique cross peaks discussed later. AT:SH2 (Figure 6-2D) has only two 
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changes at 197 nm and 216 nm. The 197 nm correlation is the largest and best 
resolved correlation out of all of those analysed using this method. The feature at 216 
nm is again broad and unresolved, possibly owing to several binding modes. 
AT:UFH (Figure 6-2E)  comprises a feature at 196 nm and at 220 nm with a possible 
feature comprising a shoulder present at 228 nm.  
 
The initial observations mark the AT:pentasaccharide as the most defined complex. 
There also seems to be a common feature between most of the complexes with the 
largest portion of variance being centered at 196 nm. This observation is to be 
expected as many structures have features in this region of the spectrum. This 
observation excludes the large and defined feature of AT:SH2, which is slightly 
shifted to 197 nm and AT:SH1 which, while containing the 196 nm also has a 
separate 192 nm feature. AT alone is the sole perturbation to exhibit its major change 
at 190 nm, immediately suggesting a different route during the perturbation. There is 
also an apparant link between AT:SH1 and AT:UFH in that they share the 220 nm  
feature in addition to the 196 nm feature.  
 
AT:Pentasaccharide (Figure 6-3), is one of the best resolved correlations in this 
series. There are observable cross peaks at 186, 195 (x 3) and 196 nm.  The values 
are obtained by referring to peak tops at the highest resolution, although these 
features obviously overlap significantly with one another. These features are 
respectively correlated with 191, 209, 213, 216 and 221nm as demonstrated through 
their cross-peaks.  
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The “double” set of cross peaks that run parallel to each other (Figure 6-4, ~195 nm) 
in AT:SH1 might also suggest that there are two distinct populations of interactions 
within this solution, one independent of all others observed here with its major 
changes at 192 nm and 231 nm, and the parallel one which has similarities with 
AT:UFH with its major changes at 196 nm and 220 nm. 
 
6.3.2. Discussion of method 2. The deduction of one AT covariance matrix from 
another. 
 
These results can be analysed further using what was referred to as the second 
method in Table 6-1. This method entails deducting the covariance matrix of one 
AT:GAG complex perturbation from that of AT:GAG complex perturbation. This 
analysis method has some limitations in that some artifacts are apparent – this 
especially appears to be the case at the higher wavelengths where no signals are 
expected – so, for this analysis all peaks above 235 nm will be ignored, and some 
attempt to remove signals of similar amplitude when they arise in illogical places 
will be made.  There are many more signals originating at 185/186 nm in the 
following data, revealing potentially important differences between some spectra. 
These features are reliable owing to the data being collected reliably to 183 nm 
below the 700 mV limit for the detector (data not shown). These data were then 
analysed from 185 nm, thus avoiding any artifacts from a saturated detector. 
 
Figures 6-5 and 6-6 correspond to this data analysis method with the first complex 
quoted in the main title being the matrix from which the covariance matrix of the 
second complex is deducted.  
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Figure 6-5 compares the relatively highly resolved AT:pentasaccharide with that of 
AT:SH1. The differences between these correlations are listed in Table 6-2. 
 
Table 6- 2: The resolvable features present in Figure 6-5 
Wavelength(s) Auto/Cross peak Sign Notes 
185 nm Auto peak Negative - 
192 nm Auto peak Negative - 
198 nm Auto peak Positive - 
218 nm Auto peak Negative - 
231 nm Auto peak Negative - 
186 / 196 nm Cross Peak Positive - 
186 / 219 nm Cross Peak Negative - 
186 / 229 nm Cross Peak Negative - 
186 / 231 nm Cross Peak Negative - 
192 / 196 nm Cross Peak Negative - 
193 / 217 nm Cross Peak Positive - 
193 / 231 nm Cross Peak Positive - 
197 / 217 nm Cross Peak Positive - 
197 / 231 nm Cross Peak Positive - 
220 / 230 nm Cross Peak Negative - 
 
This set of data reveals many differences between the two correlations, and adds 
resolution when studying how these two complexes respond to UV irradiation. The 
auto correlation peaks that are negative all refer to features that are related to 
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AT:SH1 while, conversely, the positive auto correlations refer to those stemming 
originally from AT:pentasaccharide. This is due to the amplitudes in the original 
(method 1) covariance matrices. The resolved and broad unresolved feature in the 
AT:SH1 correlation at 186 nm are here resolved into 4 separate features that mark 
part of this complex as being different from that of AT:pentasaccharide. In the initial 
analysis of Figure 6-4 (AT:SH1) it was suggested that there may be two sets of 
interactions occurring. 
 
Figure 6-6 investigates the differences between AT:Pentasaccharide and AT:UFH. 
The differences are listed in Table 6-3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The application of covariance matrix data analysis during a perturbation. 
 150 
Table 6- 3: The resolvable features present in Figure 6-6 
Wavelength(s) Auto/Cross peak Sign Notes 
185 nm Auto peak Negative - 
192 nm Auto peak Positive - 
198 nm Auto peak Negative - 
218 nm Auto peak Negative - 
187 / 196 nm Cross peak Positive - 
193 / 227 nm Cross Peak Positive - 
195 / 227 nm Cross Peak Positive - 
196 / 202 nm Cross Peak Positive - 
196 / 204 nm Cross Peak Positive Shoulder 
196 / 212 nm Cross Peak Positive - 
196 / 217 nm Cross Peak Positive - 
196 / 234 nm Cross Peak Positive - 
202 / 210 nm Cross Peak Negative - 
202 / 214 nm Cross Peak Negative - 
202 / 218 nm Cross Peak Negative - 
204 / 218 nm Cross Peak Negative - 
208 / 214 nm Cross Peak Positive - 
208 / 223 nm Cross Peak Positive - 
219 / 226 nm Cross Peak Positive - 
 
Considering the changes listed in Table 6-3 the first noticeable thing is that there are 
many subtle differences between the spectra. Some of the apparent changes, 
however, are explained by differences in scale; the difference at 195 and 196 nm 
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occurs in both spectra, with ~5 units difference between them. This indicates that 
similar changes in the raw data occur around this point between the spectra. 
However, it does show that those in AT:UFH are more heavily correlated than those 
in AT:pentasaccharude, as expected from the more extensive degradation apparent in  
the PCA analysis shown in Figure 5-4 of Chapter 5. However, there are many small 
differences observable above 200 nm, showing this region to be of particular interest 
in separating out similar interactions during this degradation.  
 
In summary, this method of investigating correlations along a perturbation appears to 
be capable of revealing more highly resolved features within comparisons of a 
similar scale. This is exemplified by the added detail contained in Figure 6-5 
AT:pentasaccharide v AT:SH1.  It suffers, however, with a scaling issue in its 
current form. Normalisation (Method 4, Table 6-1) may add better feature resolution, 
but lose information regarding the extent to which changes have occurred. This is 
arguably less important when there are other techniques that are better suited to 
interpreting the extent of changes occurring within the original raw data.  
 
6.3.3. Discussion of AT perturbations subjected to analysis method 3, MC of 
data across two perturbations to be compared. 
 
As can be seen in Figures 6-7 and 6-8, there appears to be an overall loss in 
resolution when looking at the synchronous covariance matrix. However, this type of 
analysis appears to reveal some asynchronous correlations not present in other forms 
of covariant analysis (Figure 6-8). These types of correlations can reveal information 
regarding the sequential order of events taking place within a perturbation, and report 
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those events that happen out of phase with the progression through the perturbation 
(explained in section 6.3.1. Figure 6-21). 
 
Figures 6-7 and 6-8 show the synchronous and asynchronous correlations of the 
perturbation of AT:pentasaccharide when mean centered together with AT:SH1. This 
case was chosen as an example as it reveals differences between the active complex 
of AT:pentasaccharide and the structurally similar but inactive complex of AT:SH1 
(See Chapter 5). This method of MC across two perturbations before the independent 
correlations are made removes the common features between them. These 
correlations show no signs of the complicated features that are present in the HEWL 
examples of this analysis (Figures 6-13 - 6-20) and are explained later in this chapter 
(Section 6.3.8), meaning that the sequential information can be gathered from the 
asynchronous data. 
 
Figure 6-7, showing the synchronous covariance matrix of AT:pentasaccharide when 
mean centered with AT:SH1 has two auto correlations at 203/235 nm. There are also 
cross peaks between 187/194 nm (negative sign), 193/212 nm (broad along the 193 
axis, negative sign) and finally between 203/237 nm (positive sign).   
 
Shown in Figure 6-8 is the asynchronous correlation for the perturbation presented in 
Figure 6-7. It is immediately apparent that this correlation is relatively information 
rich, especially when it is considered that other analysis techniques do not present the 
user in these examples with sequential information regarding the order of events. 
There are 7 cross peaks when all features that appear below 245 nm are considered, 
these arise from ten positions on the diagonal, referred to here as A-J. There are 
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features present at 185 (A), 195 (B), 198 (C), 208 (D), 209 (E), 214 (F), 221 (G), 237 
(H), 240 (I), and 244 nm (J). when the center of peak tops are considered it can be 
deduced that there are 4 independent events taking place, and the order given to them 
as described in section 6.3.1 by taking into account the signs of the features. From 
this we conclude that A/H precedes a change in B, that a change in D happens before 
C and that E/F/G happen before I, while finally G also changes before J. 
 
6.3.4. Discussion of AT perturbations subjected to analysis Method 4; The 
prenormalisation of covariance matrices before deduction from one another. 
 
An alternative method of analysis is shown in Figures 6-9 – 6-10. These figures 
feature comparisons between complexes that initially had problems with scaling due 
to the larger contributions of AT:SH2 to the subsequent covariance matrix. Here all 
feature heights have been prenormalised to the same scale before deductions were 
made. This removes any information regarding the extent of each change but, as can 
be observed in these example figures, a much higher resolution is achieved in 
comparison to those achieved in method 2. This is especially evident through the 
large broad feature along the axis of 199 nm from AT:SH2. These features are now 
resolved into several individually identifiable peaks. 
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6.3.5. Discussion of AT perturbations subjected to method 5, accounting for the 
extra noise inherent in the 260 nm data point. 
 
Finally, as there appear to be artifacts observed around ~260 nm, easily seen in 
Figure 6-2, a variant of the original (method 1) method was tested. This method 
(method 5, Table 6-1.) takes into account the need for equal variance along the data 
vector when mean centering is used, therefore, as noted in Chapter 7, there is 
increased noise initially during the recording of a spectrum. To eradicate the effect of 
this noise, only the wavelengths 185 to 250 nm have been considered (Method 5), 
thereby ensuring the equal variance consideration is fulfilled. As can be observed by 
the summary in Figure 6-11, there is no difference between this and the summary 
shown in Figure 6-1. This shows that, despite the observed artifact in Figure 6-2 and 
in some of the subsequent correlations, this has no material effect on the 
interpretation, as long as the user is aware of the possibility of these features arising. 
 
6.3.6. Discussion of method 1, basic covariance matrices applied to HEWL 
perturbations. 
 
The analysis of data from the HEWL 60 scan UV degradation presented in Figure 3-
5 of Chapter 3 is now analysed in the same way. This enables the comparison of two 
different systems to further assess the suitability of this method as a technique 
capable of adding information to the raw data presented, and also to the PCA that 
was carried out on this type of data and this is shown in Figure 3-7. Data is not 
presented here for Method 1 for the HEWL perturbations as the correlations given 
are of broad, uninformative features in the synchronous covariance matricies and no 
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features present in the asynchronous.  Although not presented and of low resolution, 
this did have some differences in their absolute feature positions, thereby providing 
additional information to supplement the PCA analysis previously published on this 
data set [142]. 
 
6.3.7. Method 3 applied to HEWL degradation data. A method to show subtle 
events arising from factors other than band intensity changes within a data set. 
 
The following method of analysis, shown in Figures 6-13 to 6-20, reveals that these 
UV degradations are much more complex than previously shown (PCA analysis, 
Chapter 3), offering valuable information in the patterns created. This method MC 
across the two perturbations being investigated before separate covariance matricies 
are created in order to remove any common features in the two spectra. The patterns, 
not observed in the AT data, will now be described briefly. 
 
The patterns in the synchronous and asynchronous covariance matrices demonstrate 
that the rules previously discussed in Figure 6-21 cannot be used in the analysis of 
Figures 6-13 to 6-20. The synchronous four leaf clover patterns are indicative of two 
complex spectral features, either two separate bands with intensity changes, or a 
single band shifting position. These two possibilities are then differentiated via the 
asynchronous matrix, with the band shifting position giving rise to the elongated 
features parallel to the diagonal, whereas the simpler two overlapping bands 
changing in intensity would give rise to two “spots” on the asynchronous matrix 
[217]. The four-leaf clover might be observed in Figure 6-15. 
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Another process can be identified where there is a band shifting position, coupled 
with an intensity change. Again identified via a four-leaf clover pattern on the 
synchronous matrix, this time the pattern may be asymmetrical giving rise to an 
“angel” pattern (Figure 6-13, 185 – 220 nm). This can be confused with other 
features, so again the asynchronous covariance matrix assists the identification where 
there is an elongated feature parallel to the diagonal. This time however, one “leg” 
will be longer than the other, biased towards the dominant auto peak (angel’s legs) 
on the synchronous matrix (Figure 6-14, 185 – 220 nm). There is one more process 
that is identifiable – line broadening, which is described in the literature [217] and 
does not feature in this set of data.   
 
These patterns are very sensitive, with 0.5% shifts in intensity and position being 
reported to give rise to these distinctive patterns [217]. There is information 
contained within these patterns, the centre of the four-leaf clover is the average 
feature position during the perturbation, and the signs of the elongated features in the 
asynchronous give information on the direction of the band shifting. The features 
themselves are insensitive generally to the extent of shifting, with the only direct 
correlation coming from the amplitude of the features. 
 
The synchronous covariance shown in Figure 6-13 is of HEWL mean centered with 
HEWL:HS. There is a four-leaf clover pattern, centered at 199 nm. The elongated 
features in Figure 6-14 show this to be a single band shift coupled with an intensity 
change. The feature is shifting from the left to the right – deduced via the positive 
feature being above the diagonal.  
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There are again the same features present in Figures 6-15 and 6-16, with the clover 
being centered at 199 nm. The asynchronous this time suggests that the movement of 
this feature is from right to left in the spectra. The scale of this matrix indicates that, 
in this instance, the shift of the position is larger than for HEWL. 
 
The following four figures (Figures 6-17 – 6-20) come from HEWL in both ligand 
states mean centered against one another. This case appears to be slightly more 
complex though, it is apparent that there is some band shifting taking place, and 
initially appears as if it is again coupled with band intensity changes. However, when 
looking at the asynchronous correlations, the elongated features do not appear to be 
biased towards one side of the four-leaf clover, indicating instead that it is a simple 
position shift in a band, with no intensity changes. If this is the case, then there is 
extra information contained within this analysis that cannot be elucidated currently. 
The HS form has a band shift from the right to the left of the spectra, while the 
HS(Zn) form from left to right, and in this instance there is about equal distance in 
the shift. This analysis is hindered by the position of the features been cut off by the 
edges of the plot, leading to some distinctive components not being present as 
described by Noda [217]. 
 
The analysis undertaken here has shown itself capable of adding greater resolution to 
spectra following a perturbation. This improved resolution has enabled the 
distinction between complexes that hitherto were indistinguishable structurally via 
the standard data analysis techniques of protein structure deconvolution, degradation 
via UV irradiation and the analysis of the raw data by PCA. It is possible with this 
technique to distinguish several independent contributing features in and around the 
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usually complex features apparent at 190-195 nm. The improved resolution however 
opens up several more challenges that will need to be overcome in order to further 
the assignment of structural features that are changing during a perturbation. There 
could be an issue with certain structures, such as an -helix having multiple and 
differing local environments for each chain (in this example there are several 
separate helices with one becoming extended upon ligand binding), which may shift 
the peak positions of its transitions. As mentioned previously, these overlap with 
major features for other known structural elements making the assignment at this 
position difficult.  
 
6.3.8. Discussion of HEWL perturbations analysed by Method 4; the 
prenormalisation of covariance matricies before deduction from one another. 
 
If the covariance matrices created using Method 1 were probed for differences 
through normalization of the covariance matrices and then deducted from one 
another to allow for a direct comparison, subtle differences reveal themselves. Figure 
6-12 is highly resolved, and is comparing HEWL and HEWL:HS(Zn). There are 
three auto correlations at 185, 192 and 218 nm. Then, in addition, a cross peak 
between 185 / 194 nm, and three from 195 / to 210, 218 / 226 nm, with a final cross 
peak between 218/226 nm.  
 
6.3.9. General discussion of results. 
 
It would appear that a combination of the methods presented in this chapter would be 
the best approach in any future work. The standard way of analyzing the 
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perturbations by 2D correlations, while adding information to supplement other 
analysis techniques, still gives the lowest resolution of all the methods investigated 
in this chapter. Taking these correlations and deducting the perturbations to be 
compared does increase the resolution, however, these tend to be biased towards the 
correlation with the largest scale. This is helpful to compare the extent of change at 
given correlations, but other analyses such as PCA could do this job.  The method 
whereby two covariance matrices, that have been normalised to the highest peak 
from both spectra offers the best resolution of the differences and should be used for 
that purpose (Method 4). This method is well understood as each difference 
covariance matrix created with Method 4 stems from those created in the well-
studied first method.  
 
Mean centering across two perturbations to be compared before analyzing the 
perturbations independently by 2D correlations, offers an alternative route, and 
within these two experiments appears to supplement the other data significantly. This 
method works on the basis of eliminating, or reducing, features that are in common 
between the two perturbations before correlations are applied and thereby reveals 
more subtle differences that are hidden underneath the dominating major features. 
This serves to reveal previously unobserved features, especially apparent in these 
two examples. In the AT data series, new features are revealed, most noticeably in 
the asynchronous matrix, whereby some sequential information along the 
perturbation can be elucidated. This could provide in-depth structural information on 
the processes being observed when compared to previous analysis techniques. In the 
lysozyme experimental set, the analysis also reveals some subtle band shifting and 
overlapping signals with high sensitivity. This information will be vital if 
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quantitative secondary structures are to be elucidated at each step of a degradation, 
because algorithms assume that features have independent peaks, whose intensity 
changes depend on the contribution of that feature. In this study, it would be 
inappropriate to apply these structural analyses to the HEWL perturbations. 
Conversely, the lack of the distinctive features in the AT perturbations means that 
structural information can be gained at any stage during the perturbation, and any 
analysis that is applied is limited by signal to noise ratios and the quality of the 
algorithm without being complicated by any line broadening, shifting or overlapping 
features that change intensity. This also means that the peak tops in the AT case are 
reliable indicators of separate features, so much higher resolution can be obtained. 
For example, features differing by 1 or 2 nm can reliably be taken as two separate 
features rather than just one broad feature with low resolution. 
 
In future analysis and data mineing of a peturbation should include a 
combination of Methods 1, 3 and 4. This would give the best range of results and 
information to added to more standard analysis techniques, although care 
should be taken in the appropriate pretreatment of data [2]. 
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Chapter 7. Improvements to data handling for Raman optical 
activity and SRCD spectroscopy. 
 
This chapter will describe two developments in the handling of general spectroscopic 
data, including those that involve GAGs. The first development will look at Raman 
and ROA spectra, where a method has been developed for the correction of baseline 
drifts and the normalisation of data. The method is intended for Raman and ROA 
data but, in principle, could be applied to any spectroscopic technique where the 
need arises. Secondly, the new method for normalisation of SRCD will be 
demonstrated. The need arose after the observation of an increase in noise at the 
initial data point (260 nm) within a SRCD spectrum. This will be demonstrated here, 
with the new method as a comparison.  
 
7.1. Development of a baseline subtraction method for Raman and Raman 
Optical Activity spectroscopy. 
 
Raman spectroscopy is the basis for ROA and stems from inelastic scattering from a 
molecule whose polarisability changes through interaction with the electric field of 
the incident radiation. The inelastic scattering originates through Stokes and anti-
Stokes contributions, see Figure 7-1. There have been Raman spectra reported for 
monosaccharides [218] and polysaccharides in the Raman with assignments [219]. 
This technique is highly complementary to IR spectroscopy and can give information 
on conformational states of molecules, with signals arising over very short time 
scales, for example at 1000 cm
-1
 a transition will take ~10
-14- 
s [220].  
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Figure 7- 1: The energy transitions involved in Raman scattering compared 
to the more common phenomenon Rayleigh scattering.  Raman scattering is 
split into two categories, Stokes, and anti-Stokes. ROA is the result of the 
differences between optically active Raman scattering molecules in the 
presence of L and R polarised light. 
 
ROA is an extension of the Raman and stems from the difference in intensity 
between Raman scattering of right and left handed circulary polarised radiation from 
a chiral molecule, much like that reported for SRCD. The signal arising from this 
technique is very weak, however, the potential information is potentially of great 
value in attempts to elucidate some form of structure-function relationship for the 
GAG component of protein-GAG interactions. ROA is highly sensitive to 
conformational features [221], for example the geometry of the glycosidic linkage 
and sugar puckering [222,223,224,225,226]. Of particular interest is the possibility 
that this technique could report helicity in solution for polysaccharides [82]. With 
this in mind, and following on from recent developments where the first full length 
GAGs were investigated in solution by ROA [227,228], a set of experiments were 
devised to attempt to better assign features observed in carbohydrate (heparin) ROA 
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spectra via the 2D heterocorrelation of a perturbation recorded in the ROA with 
reference to NMR where signal positions for each atom are fully mapped in heparin 
[30]. The perturbation employed was the addition of a cation manganese (Mn
2+ 
in the 
form of MnCl2) that was shown to interact with, and alter the conformation of, 
heparin (Figure 7-2, and NMR (data not shown)). This perturbation was performed 
and data recorded. However, owing to a malfunction in one of the components of the 
ROA equipment the data were not of sufficient quality to use as intended. The 
analysis of the ROA data has led to a method for baseline correction in the technique 
and this will be described below.  
 
Figure 7-2 shows the raw data for the Raman (upper panel) and ROA (lower panel) 
spectra for the titration of MnCl2 into heparin in the original form of handling the 
data, normalised to a featureless point of the ROA spectrum. The Raman spectra 
should contain only positive points, while ROA should consist of negative and 
positive features based around zero units. 
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Figure 7- 2: Titration of MnCl2 (0 – 1.8 mg /ml) in 0.2 mg/ml steps into a 
heparin solution (300 mg/ml) in 90% H2O and 10% D2O, recorded for 18300 
scans, 1.029 s exposure per scan and 0.30 W laser strength (532 nm). The 
data have been normalised at 1592 cm-1. All samples were centrifuged for 10 
minutes at 30k rcf and pre-illuminated using a full strength laser for 30 
minutes prior to recording. 
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The spectra presented in Figure 7-2 have a clear baseline drift despite being 
normalised to a featureless region of the spectrum (1592 cm
-1
). In order for 
comparisons between spectra to be made, this drift needs to be corrected for. The 
first step in this for the Raman and ROA data collected here is to perform a spline fit 
(using the Forsythe, Malcolm and Moler method) for the x-axis data collected in 
order to assign the data points to the same position across all spectra. This is 
necessary because each spectrum contains a recorded wavelength to 3 decimal places 
for each data point, and is different in each spectrum. After completion of this step a 
background spectrum is created for each individual spectrum, here presented for the 
spectrum of heparin (Figure 7-3) and deducted from the raw data. 
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Figure 7- 3: Circles: Raw data of ROA spectrum of heparin (300 mg/ml) in 
90% H2O and 10% D2O. ROA recorded for 18300 scans, 1.029 s exposure 
per scan and 0.30 W laser strength (532 nm). Solid black line: Raw data 
smoothed using a forwards and reverse pass filter of 200 data points using 
the R function “filtfilt” [229]. 
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The raw ROA data were taken and smoothed by applying a forwards and reverse 
pass filter over 200 data points to create the solid black line shown in Figure 7-3. 
This solid line for each individual spectrum was then deducted from the 
corresponding raw data spectrum to apply a baseline correction; this serves to flatten 
the spectra, correcting for drifts introduced during the recording of the data. These 
data were then smoothed again over 2 data points in the same manner, to reduce 
noise in the spectrum, at the expense of resolution. This smoothed data is then 
deducted from the baseline corrected spectrum and is shown in Figure 7-4. 
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Figure 7- 4: Circles: Baseline corrected data of the ROA spectrum of heparin 
solution (300 mg/ml) in 90% H2O and 10% D2O, recorded for 18300 scans, 
1.029 s exposure per scan and 0.30 W laser strength (532 nm). These data 
have been smoothed again over 2 data points to reduce noise. Solid red line: 
Original raw data presented in Figure 7-2 for comparison. 
 
The data presented in Figure 7-4 were then taken and the average value between 
1700 and 1800 cm
-1
 found, and deducted from the spectrum to give the data 
presented in Figure 7-5 (black circles). This sets the spectra to zero at a featureless 
region of the spectrum. 
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Figure 7- 5: Circles: Baseline corrected and normalised data (1700 – 1800 
cm-1) of a heparin solution (300 mg/ml) in 90% H2O and 10% D2O, recorded 
for 18300 scans, 1.029 s exposure per scan and 0.30 W laser strength (532 
nm). These data have been smoothed again over 2 data points to reduce 
noise. Solid red line: Original raw data presented in Figure 7-2 for 
comparison. 
This process was then completed across all the ROA spectra shown in Figure 7-2, 
and the results are shown below in Figure 7-6. The top panel shows the unprocessed 
data zeroed at 1592 cm
-1
 and lower panel, the baseline corrected spectra. 
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Figure 7- 6: ROA spectra of a titration of MnCl2 (0 – 1.8 mg /ml) in 0.2 mg/ml 
steps into a heparin solution (300 mg/ml) in 90% H2O and 10% D2O, 
recorded for 18300 scans, 1.029 s exposure per scan and 0.30 W laser 
strength (532 nm). All samples were spun for 10 minutes at 30k rcf and pre-
illuminated using a full strength laser for 30 minutes prior to recording. Top 
panel: The data were normalised to 1592 cm-1. Lower panel: The data 
analysis method outlined in Figures 7-3 – 7-5 was applied then normalised to 
the average value between 1700 and 1800 cm-1. 
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Shown in Figure 7-6 is a comparison between the original and the new 
methodologies for dealing with ROA spectra. This new methodology gives a much 
flatter baseline – especially apparent towards the lower wavenumbers (200 – 800 cm-
1
) further away from the normalisation performed in the original data analysis 
(Figure 6, upper panel). The new baseline correction method was then applied to the 
Raman data with only minor changes to procedure and shown in Figure 7-7. 
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Figure 7- 7: ROA spectra of a titration of Mn2+ (0 – 1.8 mg /ml) in 0.2 mg/ml 
steps into a heparin solution (300 mg/ml) in 90% H2O and 10% D2O, 
recorded for 18300 scans, 1.029 s exposure per scan and 0.30 W laser 
strength (532 nm). All samples have been spun for 10 minutes at 30k rcf and 
pre-illuminated using a full strength laser for 30 minutes prior to recording. 
Top panel: Data have been normalised to 1592 cm-1. Lower panel: data 
analysis method outlined in Figures 7-3 – 7-5 were applied to correct for 
baseline via the use of a two pass filter over 100 data points, and normalised 
to the average value between 1700 and 1800 cm-1. 
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Figure 7-7 shows the result of applying the same baseline correction method to the 
Raman spectra, in this instance spectra were smoothed over 100 data points and not 
200. There is less need to reduce noise owing to the extra intensity of the Raman 
signal compared to its optically active counterpart. As can be seen the correction 
method appears to improve the quality of the baseline across all spectra presented. 
However, there are still some errors, as is apparent from the negative signals shown 
around the 800 – 1200 cm-1 region. This has been accounted for in Figure 7-8 by 
simply taking the square root of the square of the data shown in Figure 7-7 (lower 
panel) to make all data zero or positive.  
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Figure 7- 8: ROA spectra of a titration of Mn2+ (0 – 1.8 mg /ml) in 0.2 mg/ml 
steps into a heparin solution (300 mg/ml) in 90% H2O and 10% D2O, 
recorded for 18300 scans, 1.029 s exposure per scan and 0.30 W laser 
strength (532 nm). All samples have been spun for 10 minutes at 30k rcf and 
pre-illuminated by a full strength laser for 30 minutes prior to recording. Data 
analysis method outlined in Figures 7-3 – 7-5 were applied to correct for 
baseline via the use of a two pass filter over 100 data points, and normalised 
to the average value between 1700 - 1800 cm-1. Then the data were squared 
and the square root is presented here. 
Improvements to data handling for Raman optical activity and SRCD. 
 175 
Figure 7-8 shows the Raman spectra after baseline correction and the additional data 
handling to remove negative signals from the spectra. These data are much improved 
compared to the original method of handling data (Figure 7-7, upper panel), 
however, there is still obviously some room for improvement. Namely, the 
normalisation of the data appears to be incorrect, as the edge of a feature apparent at 
1700 cm
-1
 is being used as part of the normalisation. To correct for this it might be 
necessary to include more wavenumbers to find a truly featureless region at these 
wavelengths in the Raman. 
 
In this section a technique for handling data from Raman and ROA experiments has 
been proposed with the purpose of correcting erroneous baselines. While the 
experimental series itself cannot be used due to a malfunctioning component in the 
ROA equipment at the time of recording, it can be observed that this method is an 
improvement upon simply applying a normalisation to the spectra. This data 
handling technique is not limited to ROA spectra, and can be applied to any similar 
data sets such as IR spectroscopy.  As this methodology smoothes over a large 
number of data points to create a background file, resolution should not be lost in the 
deduction of a baseline and therefore maximum information is still maintained for 
interpretation. 
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7.2. Development of an improved normalisation method for far-UV SRCD. 
 
Far UVCD requires the normalisation of data to a point at which there is no signal to 
allow for direct comparisons to be made. The data point used has generally been 260 
nm, however, during the period of this body of work it was noted that this initial 
point has a large error (Table 7-1), which can introduce artifacts into subsequent 
analysis such as elucidating secondary structure information from spectra. Therefore, 
alternative to normalisation at 260 nm, the averages between 250 and 255 nm, an 
area of the spectrum that is still devoid of protein signals in far UVCD. The standard 
deviations of ten randomly selected spectra from the SRCD work during the PhD 
project are presented in Table 7-1. 
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Table 7- 1: A comparison between a selection of 10 spectra taken over the course of this body of work to compare between the 
error of the original method of normalising data at 260 nm, and the improved method of normalising data to the average of 250 -255 
nm. Values given are the SD of the mean CD signal in that sample at the wavelengths stated. 
File Sample Buffer Path length 260 nm (SD) 250 – 255 nm (SD) 
151212b05 IL-8 1 mg/ml 
 
137 mM NaCl PBS 0.2 mm 1.026 0.424 
110513b22 Galectin 0.5 mg/ml 137 mM NaCl PBS 
 
0.1 mm 0.491 0.083 
110513b01 Galectin (0.5 mg/ml), “E”  (0.5 mg/ml) 
 
137 mM NaCl PBS 0.1 mm 0.360 0.111 
110513b26 FGF2 (26 µM) 137 mM NaCl PBS 0.1 mm 0.459 0.101 
260514b05 Antithrombin 0.4 mg/ml 12.5 mM NaCl PBS 0.2 mm 0.840 0.046 
260514b12 Antithrombin (1.7 mg/ml), NA heparin (1:1)  
 
12.5 mM NaCl PBS 0.2 mm 0.472 0.085 
071211b04 HEWL 0.5 mg/ml 12.5 mM NaCl PBS 0.2 mm 0.201 0.096 
071211b10 HEWL (0.5 mg/ml), HS (0.08 mg/ml) 12.5 mM NaCl PBS 0.2 mm 0.377 0.064 
040512b33 Antithrombin  0.4 mg/ml 12.5 mM NaCl PBS 0.1 mm  0.168 0.044 
040512b21 Antithrombin (0.4 mg/ml), UFH (0.8 mg/ml) 12.5 mM NaCl PBS 0.1 mm 0.667 0.063 
                                                                                                                                           Average 0.506 0.112 
                                                                                                                                           SD 0.270 0.112 
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As shown by Table 7-1, the method of normalising data as used at the beginning of 
this body of work [142] is less reliable at creating a zero point from which spectra 
can develop their features. The alteration of this method to one where the average of 
250 – 255 nm is used reduced the error incurred by over 75% and has since been 
used for data handling [141]. This data handling point is a crucial step when 
processing circular dichroism data as algorithms, such as the one used predominantly 
for the work within this project [98]. It requires that all spectra are normalised to zero 
at 260 nm, and any added error when applying this requirement could lead to an 
amplification of errors when deducing the average secondary structures from spectra.   
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Chapter 8: Conclusions. 
 
This thesis covers several biological systems relevant to the study of protein:GAG 
interactions and methods by which their study can be improved. Initially a model 
amyloid forming protein, HEWL, was studied. It is known that HS is associated with 
amyloid plaques and promotes their growth [126,127,128]. The result of this initial 
investigation was then carried forward into the development of a new technique to 
study Trp:GAG interactions, MCD. This technique has shown itself to be capable of 
demonstrating direct interactions between Trp residues and the HS ligands with our 
system, thereby demonstrating strong support for the hypothesized binding site 
within the substrate binding cleft of HEWL. Another system utilised during this body 
of work is the much studied AT interaction with the pentasaccharide in combination 
with various other heparin derivatives and also non-active (against anti factor Xa) 
SHs that contain the rare 3-O-sulfate, which is often portrayed as the marker for 
active heparin fragments. Generalized 2D correlation techniques [217] were 
employed to attempt to increase the amount and quality of information gathered from 
CD experiments. Separately a simple data handling method for ROA and Raman 
data has been proposed in order to correct for baseline drifts within a data set to 
allow for direct comparisons between a series of measurements. 
 
The HEWL complexes, investigated in Chapter 3, were all created at pH 7, in a 12.5 
mM NaCl PBS buffer. The aggregation, and destabilisation, of HEWL would be 
interesting to investigate further and may have implications for potential routes to 
amyloid formation within physiological conditions. It has been noted that proteins at 
their pI form amyloid-like aggregates when studied using various techniques 
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[230,231]. This could be investigated as a possibility within the system used here. 
We observe the creation of a large quantity of unordered and -sheet structure (+22 
and 27% for HS and HS(Zn) ligands) which, would be consistent with the particles 
observed previously [230,231]. The pI of HEWL is close to 10.5, far removed from 
the natural pI. However, the pI of heparin molecules is extremely acidic [148],  so 
combined could conceivably shift the pI of the complex into the physiological range 
through the covering of charges upon binding and introduction of acidic groups on 
the GAG. This hypothesis is supported by preliminary data, not shown here, by 
optical density (600 nm), polarised microscopy, and dynamic light scattering 
(personal communication, Joseph Holman) of HEWL:heparin complexes over a 
range of pHs in a universal buffering system.  
 
The proposed binding site for HS on HEWL, from the near-UV data (Chapter 3, 
Figure 3-2) suggesting an interaction with Trp residues, contains two exposed Trp 
residues, out of six in total. To investigate this further MCD was utilised, in Chapter 
4, as a possible tool for investigating the tryptophan amino acid selectively. This 
provided evidence of a direct Trp:HS interaction in both cases. The MCD spectra of 
the two ligands (HS and HS(Zn)) were not statistically different from one another 
(p>0.05). The possibility remains that this technique may be capable not only of 
confirming an interaction with those amino acids, but also differentiating between 
two extremely similar interactions, through a more through data collection process, 
such as more scans (in this work n=4) to increase the confidence of the measurement. 
Further investigation of the change in spectral shape ~286 nm could be conducted 
through NMR, and also through steric hindrance of the binding site via indole 
chemistry adding chemical groups to the indole ring of Trp [150].  
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Chapter 5 focuses on AT and a range of polysaccharides with varying degrees of anti 
factor Xa activity, an important function for AT in the blood clotting cascade and the 
target for several anticoagulant drug therapies. Here it is shown that the classic 
pentasaccharide sequence, long been held as the exemplar of what is possible with 
heparin based interactions if the technology and methodology can be developed to 
sequence heparin/HS sequences to an adequate extent, gives the same secondary 
structural changes in AT as the non-active heparinoid compounds from the shrimp L. 
Vannamei. These non-active shrimp compounds contain the same 3-O-sulfate in 
glucosamine thought to be central to heparin activity in AT and also elute from an 
AT affinity column at similar binding affinities. However, these compounds, which 
are not active, induce the same secondary structures in the protein implying that, 
while a valid drug, the pentasaccharide is not the sole sulfation sequence capable of 
inducing anti Xa activity in AT. Rather, it appears there is much degeneracy between 
compounds giving a range of activities as required, allowing for a flexible system. 
This assertation is further supported by the observation of the properties of 
complexes formed from a set of generic HS chains with FGF that differ only in their 
cation state, with their overall sulfation remaining the same the change of activity on 
cation state alone [45,46] as well as observation that even non-native plant 
polysaccharides can induce activities on some targets [139] is further evidence that 
HS activity is not solely sulfate sequence based, but a combination of factors.  
 
The stability assay DSF has shown itself to be useful as a quick screen for 
compounds that may have anticoagulant activity. This is important in the search for 
new anticoagulant drugs to improve upon Arixtra as this has suffered from some 
problems such as difficulty in neutralization during surgery. In order to progress the 
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field a mind-set change is required away from the genetics doctrine of a sequence of 
repeated chemical units leading to a specific outcome to embrace one of redundancy 
and subtle changes modifying delicate balances within complex biological systems 
as the organism requires. This could be achieved through a change in cation state, or 
the removal of sulfates upon a GAG chain by the sulf enzymes as required. 
 
Chapter 6 takes the degradation data from Chapters 3 and 5 and applies generalised 
2D correlation techniques to them. The result of deducting two normalised 
covariance matrices from one another is that the resolution in each correlation can be 
increased to 1 nm in the 185-195 nm areas of the spectra. This region is where 
multiple signals overlap with one another enabling on a simplistic level, the 
distinction between extremely similar complexes. When these same degradations are 
mean centered across the two spectra to be compared, all common features are 
removed revealing the differences between the two. This has generated the useful 
feature of revealing very subtle band shifting events within the spectra. This could be 
extremely useful for the observer as it reports whether the signals observed in the 
initial 2D analysis are reliable independent features that can be deconvoluted and 
interpreted for secondary structural analysis. With the increased resolution, one idea 
for future work is to selectively label a protein with a heavy isotope eg 
13
C, and 
thereby alter subtly the electronic properties of the atoms, and selectively observe a 
particular region of a protein. This could be extremely useful, for example in the AT 
case, as it would be useful to know if the secondary structural changes observed in 
Chapter 5 occur in the same region of the protein. 
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Chapter 7 provides an additional data handling technique suitable for any spectral 
data set, but designed for ROA data. A simple method has been developed to correct 
for baseline drift through a spectrum to allow for comparisons to be made throughout 
an experimental series recorded in ROA and Raman. The methods need to be 
improved, especially for the Raman correction as the final square and square root 
step (See Figure 7-8 of Chapter 7) introduces some artifacts in the removal of 
negative features, a Pareto scaling method, or some other form of weighted 
correction would greatly improve this correction method.  
 
Overall, the future of CD should be considered fairly bright if used, as it should be, 
in conjunction with complementary techniques. With the new data analysis methods 
it is now possible to gain high-resolution information on data series. Here, 
degradation data has been used but any series of data such as a ligand titration would 
be perfectly acceptable. This enables the deconvolution of the information rich 185-
195 nm region of the spectrum where many contributions overlap and could improve 
greatly the reliability of the structural information gained if used together with high 
quality algorithms. There is also the possibility with this higher resolution to 
selectively look at a particular region of the protein through labels that effect the 
electronic configuration of the protein and therefore the absorption properties. Away 
from CD, ROA is another promising technique that unfortunately was unable to be 
investigated further during the course of this PhD, but with its capacity to prove 
GAG conformation and helicity in solution could go some way to building an 
appreciation for the requirements between active and non-active compounds. This 
would be an ideal opportunity to utilise generalised 2D correlation techniques to 
Conclusions. 
 184 
heterocorrelate between the unassigned ROA spectra and the previously assigned 
NMR spectra, thus assigning changes observed in one to known chemical groups. 
 
In conclusion, CD and other techniques reported in this thesis offer additional 
capabilities for the study of protein:GAG complexes in solution.  
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